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Abstract 
 
 p27kip1 binds to and regulates the activity of cyclin-dependent kinases 
(Cdks) which are the master timekeepers of the cell division cycle. Members of 
the p27 family of proteins, also including p21 and p57, are called cyclin-
dependent kinase inhibitors (CKIs).  The amino terminal domain of p27 inhibits 
Cdk activity and is referred to as the kinase inhibitory domain (KID).  The KID is 
comprised of a cyclin-binding domain (D1) and a Cdk binding domain (D2) joined 
by a 22 residue linker domain (LH).  Structural analysis of the KID in solution 
before binding its Cdk targets revealed that D1 and D2 are largely unstructured 
and that the linker domain exhibits nascent helical characteristics.  The nascent 
helical structure of the linker domain is conserved amongst the CKI proteins and I 
hypothesize that it is an important determinant of their functional properties. To 
test this hypothesis, I probed the interactions of peptides corresponding to D1 
and D2 (LH domain deletion mutant) with the Cdk2/cyclin A complex.  Results 
from isothermal titration calorimetry (ITC) and kinase inhibition assays, show that 
the interaction and of either D1 or D2 with the Cdk2/cyclin A complex is less 
favorable relative to that of the p27-KID and that the D2 peptide cannot 
completely inhibit Cdk2/cyclin A kinase activity.  These results indicate that the 
LH domain that couples D1 and D2 is necessary for the function of p27 as a Cdk 
inhibitor.   
 Despite having a conserved structure, the linker domains of the Cip/Kip 
proteins do not have a conserved sequence.  However, the sequence of this 
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domain in each Cip/Kip protein in different species is well conserved suggesting 
that sequence may play a role in the function of these proteins.  I explored this 
sequence-divergence/structure-conservation relationship of the linker domains of 
the Cip/Kip proteins by constructing chimeric p27-KID molecules in which the p27 
linker domain was replaced with the corresponding segments of either p21 or 
p57.  ITC and kinase inhibition assay results show that the chimeric molecules 
bind and inhibit Cdk2/cyclin A in a manner similar to that of p27-KID.  Moreover, 
thermal denaturation studies show that the complexes formed by these proteins 
bound to Cdk2/cyclin A have comparable melting temperatures.  Taken together, 
these results indicate that the different linker domains, despite their structural 
differences, play similar structural roles in p27 binding to Cdk2/cyclin A. 
 In a third study, I investigated the consequences of perturbing the 
conserved structure of the linker domain.  I successfully designed and prepared 
p27 variants in which domain LH was either more or less helical with respect to 
the wild-type protein.  The secondary structural properties of the mutants were 
characterized by circular dichroism spectropolarimetry (CD).  Thermal 
denaturation experiments showed that the ternary complexes of the p27 variants 
bound to Cdk2/cyclin A were less stable compared to the ternary complex formed 
by wild-type p27(p27-KIDwt).  Thermodynamic analysis showed that there was a 
decrease in the enthalpy of association of the mutants with Cdk2/cyclin A relative 
to p27-KIDwt.  The free energies of binding varied within a much narrower range.  
In addition, in vitro Cdk2 inhibition assays showed that the p27 variants exhibited 
disparate inhibitory potencies.  Further, when we over-expressed the p27 
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variants in mouse fibroblasts, they were less effective in causing cell cycle arrest 
relative to wild-type p27.  These results indicate that the conserved structure of 
the linker domain is important for p27 function.  It seems that nature has selected 
the sequence of the p27 LH domain to be partially structured and that bolstering 
or eliminating this structure is deleterious to function; intrinsic structure is critical 
for function.  
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Chapter 1: Introduction 
 
 Self-replication is a fundamental property of eukaryotic cells.  A complex, 
coordinated succession of events ensures that the parent cell is divided into two 
identical daughter cells.  The sequence of events that take place between one 
cell division and the next is referred to as the cell division cycle or the cell 
cycle.1,2  This series of events can be separated into four distinct phases:  
• G1 phase – characterized by cell growth, synthesis of new organelles, 
increased protein synthesis, and an accelerated metabolic rate.   
• S phase – characterized by synthesis of deoxyribonucleic acid (DNA). 
• G2 phase – the cells prepare for mitosis and checkpoints ensure that any 
insults to the genome since the previous division are not propagated.  The 
G1, S and G2 phases are collectively referred to as interphase. 
• M phase – the genetic material is divided into two identical fractions  
(mitosis) and the cell divides into two daughter cells each containing one 
half of the genetic material (cytokinesis).        
Proliferating cells may exit the cell cycle temporarily, or reversibly, and enter into 
a state called quiescence or G0 phase.  Cells typically enter the G0 phase from 
the G1 phase.  Figure 1.1 shows the various phases of the cell cycle.   
The cell cycle is one of the most extensively regulated processes in eukaryotic 
organisms.  A number of proteins including kinases, kinase activators and 
inhibitors, phosphatases, and transcription factors, just to mention but a few, are 
involved in the modulation of the cell division cycle.
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Figure 1.1 Schematic diagram of the eukaryotic cell division cycle.   
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1.1 Cyclin-dependent kinases  
 Strict temporal control of cell cycle progression is required for faithful 
duplication of eukaryotic cells.  This is achieved predominantly through the 
activity of a family of highly conserved serine/threonine kinases called cyclin-
dependent kinases (Cdk’s).3-11  The Cdk’s govern phase transitions during the 
cell cycle in a timely manner and are referred to as “master timekeepers” of the 
cell cycle.12  Two events are required for complete activation of the Cdk’s:  (i) a 
regulatory subunit called a cyclin binds to the Cdk;13-19 and (ii) the Cdk is 
phophorylated on a conserved threonine residue (T160 in Cdk2) by a family of 
proteins called Cdk-activating kinases (CAK’s).20-27  The kinase active site is 
located in the Cdk subunit of the heterodimer.  Upon activation, the Cdk’s 
phosphorylate a number of substrates orchestrating an orderly progression of the 
cell cycle from one phase to the next.  As an example, Cdk4/cyclin D, 
Cdk2/cyclin A and Cdk2/cyclin E phosphorylate the retinoblastoma (Rb) protein 
facilitating the transition of proliferating cells from the G1 to the S phase.28-31  In 
the hypophosphorylated state, the Rb protein represses transcription by binding 
and negatively regulating the activity of transcription factors such as the E2F 
family of transcription factors, chromatin remodeling complexes, and histone 
deacetylases.32-34  Phosphorylation of the Rb protein by the Cdk complexes 
relieves its repressor activity and activates the transcription factors culminating in 
progression from G1 to S phase. 
 The protein level of the cyclins oscillates depending on the phase of the 
cell cycle ensuring that the Cdk’s are activated at the appropriate time.35  The 
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abundance of the cyclins in any cell cycle phase is regulated through 
programmed synthesis and degradation.17  A classic example is the regulation of 
protein levels of cyclin E and cyclin B.  The synthesis of cyclin E is induced in late 
G1 and its level peaks at the G1 to S transition.36  As previously mentioned, 
cyclin E activates Cdk2 and promotes G1 to S transition.  However, as the S 
phase starts and progresses, cyclin E activity is no longer required and its protein 
levels are reduced by degradation.17  Cdk1/cyclin B is required for the G2/M 
transition and cyclin B synthesis is induced in late S phase.37  The cyclin B 
accumulates in complexes with Cdk1 as the cells approach the G2 to M 
transition.37  When the cells enter the M phase, cyclin B is rapidly degraded.37  In 
addition to cyclins, other regulators of cell cycle are also temporally degraded to 
ensure proper progression of the cell cycle.35,38  Protein degradation is therefore 
an important regulatory mechanism in cell cycle progression.   
 The Cdk’s were originally discovered in yeast where they were shown to 
be indispensable players in progression of the cell cycle.  The Saccharomyces 
cerevisiae Cdk, Cdc2, and the Saccharomyces pombe Cdk, Cdc28, were the first 
to be identified.39-41  The human orthologs were soon discovered based on their 
capacity to complement yeast mutants.42  In yeast, only a single Cdk regulates 
cell cycle events.  In contrast, the cell cycle in higher eukaryotes is regulated by 
multiple Cdk’s.  To date, 11 Cdk’s (Cdk 1-11) and 9 Cdk-related proteins have 
been identified.4  It is important to note that not all the Cdk’s and Cdk-related 
proteins are involved in cell cycle progression (Table 1.1).  Only Cdk’s 1, 2, 4, 
and 6 have been directly implicated in cell cycle progression.  On the other hand,  
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Table 1.1 Cyclins, cyclin-dependent kinases and their biological roles. 
 
 
Cdk Associated cyclin(s) Function 
Cdk1 Cyclins A, B, E Regulation of G1-S, G2-M transitions 
Cdk2 Cyclins A, E Regulation of G1-S transition 
Cdk3 Cyclins E, A, C Cell cycle exit 
Cdk4 Cyclins D1, D2, D3 Regulation of G1-S transition 
Cdk5 Cyclins p35, p39 Neuronal regulation 
Cdk6 Cyclins D1, D2, D3 Regulation of G1-S transition 
Cdk7 Cyclin H Cdk-activating kinase 
Cdk8 Cyclin C Regulation of transcription 
Cdk9 Cyclins T1, T2, K Regulation of transcription 
Cdk10 Unknown Regulation of transcription 
Cdk11 Cyclins L1, L2 Regulation of transcription 
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Cdk7 acts as a CAK regulating the activity of other Cdk’s43,44 and Cdk5 is 
predominantly expressed in neurons where it is involved in the regulation of 
neuronal functions including synaptic transmission and cytoskeletal 
remodeling.45,46  Other Cdks like Cdk8 and Cdk9 are mainly involved in 
regulation of transcription.47-50  The best characterized members of the Cdk 
family are those involved in cell cycle progression.   
 Although Cdk’s have different regulatory roles in cells, their catalytic 
domains are highly conserved and have a similar three-dimensional structure.  
Past studies have shown that in the unbound Cdk’s, the active site is not properly 
configured for catalysis.51  The binding of a cyclin subunit and CAK 
phosphorylation induces conformational changes which enable the Cdk active 
site to become catalytically competent.52,53 In addition to Cdk activation, the 
cyclin subunit also contains the binding site for a number Cdk substrates.54  The 
binding site is composed of a conserved set of residues that form a hydrophobic 
patch.  Key cell cycle regulatory proteins including Rb have been shown to bind 
to this substrate-binding motif.54  Cdk activity is also regulated by inhibition.   
  Phosphorylation within the N-terminal region of Cdk’s can lead to 
inactivation.  This inactivating modification occurs on a single tyrosine residue in 
Cdk’s 4 and 6 (Y17 and Y24 of Cdk4 and Cdk6, respectively), while Cdk1 and 
Cdk2 are phosphorylated on adjacent threonine and tyrosine residues (T14 and 
Y15 on Cdk1 and Cdk2).55-59  Previous studies have demonstrated that Cdk1 and 
 Cdk2 are phosphorylated by Wee1 and Myt1 kinases.60-64  However, the 
kinase(s) that phosphorylate Cdk’s 4 and 6 have not yet been identified.  This 
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inactivating phosphorylation event is reversed by the activity of Cdc25 family of 
phosphatases.65-67  In addition to phosphorylation, Cdk activity is also inhibited by 
a family of proteins termed the cyclin-dependent kinase inhibitors. 
 
1.2 Cyclin-dependent kinase inhibitors 
 The cyclin-dependent kinase inhibitors (CKI’s) negatively regulate the 
activity of the Cdk’s.68,69  In humans, CKI’s are divided into two families: the Ink4 
family70-73 that includes p15Ink4b, p16Ink4a, p18Ink4c, and p19Ink4d; and the Cip/Kip 
family74-88 that includes p21Waf1/Cip1/Sdi1/Cap20, p27Kip1, and p57Kip2.  The Ink4 family 
inhibits Cdk activity by binding to the catalytic subunit of Cdk’s 4 and 6 abolishing 
their ability to form active complexes with D-type cyclins89 (cyclin D1, cyclin D2 
and cyclin D3; expressed in an organ and tissue specific manner37).  Figure 1.2 
shows the structures of p19/Cdk6, p16/Cdk6 and Cdk2/cyclin A complexes.  The 
PDB accession numbers for the p16/Cdk6, p19/Cdk6 and Cdk2/cyclin A are 
1BI7, 1BI8, and 1FIN, respectively.  The binding of p19 and p16 to Cdk6 distorts 
the cyclin binding site (compare with the cyclin binding site in the Cdk2/cyclin A 
complex).  By blocking cyclin D from binding, p19 and p16 maintain Cdk6 in an 
inactive state.  Cdks adopt the bilobed fold common to many protein kinases.90  
This fold is comprised of an N-terminal lobe that is largely comprised of β-sheets 
and a C-terminal lobe that is mainly comprised of α-helices.  The binding of p19 
and p16 to Cdk6 push the N and C terminal lobes away from each other resulting 
in deformation of the binding site for the D-type cyclins.   In addition, the two 
inhibitors distort the ATP binding pocket of Cdk6 contributing to further inhibition. 
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Figure 1.2 Structures of the Cdk2/cyclin A (PDB; 1FIN), p19/Cdk6 (PDB; 
1B18), and p16/Cdk6 (PDB; 1B17).  The binding of p19 and p16 to the Cdk6 
distorts the cyclin binding site preventing the formation of Cdk6/cyclin D 
complexes.  
p19 p16
Cdk6  
Cyclin ACdk2
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 On the other hand, members of the Cip/Kip family of CKI’s inhibit Cdk 
catalytic activity by binding to the heterodimeric complex over an extended 
surface spanning from the cyclin to the Cdk subunit.  The Cip/Kip proteins inhibit 
a broad spectrum of Cdk complexes and have been shown to regulate the 
activity of Cdk’s in complex with cyclins D, E and A.91,92  Figure 1.3 shows the 
versatility of the Cip/Kip proteins in Cdk regulation during the G1/S transition.  
Each Cip/Kip protein family member contains an amino terminal domain that has 
been shown to be necessary and sufficient for Cdk inhibition.  This functionally 
conserved segment is known as the kinase inhibitory domain (KID).  The 
sequences of the KID’s of p21 (residues 11 - 94) and p57 (residues 23 - 106) 
with respect to p27 (residues 22 – 106) are 48% and 42% identical.  The Cdk 
regulatory activity of the Cip/Kip proteins causes cell cycle arrest during the G1/S 
transition.  This phase transition is controlled by Cdk1/cyclin A or E, Cdk2/cyclin 
A or E, Cdk4/cyclin D, and Cdk6/cyclin D.  While the inhibition of Cdk1 and Cdk2 
complexes by the Cip/Kip proteins is well defined, their effect on Cdk’s 4 and 6 is 
less clear.  Early studies on the interaction of the Cip/Kip proteins with 
Cdk4/cyclin D and Cdk6/cyclin D complexes reported that the Cip/Kip proteins 
promote assembly of Cdk4/cyclin D and Cdk6/cyclin D complexes, in essence 
acting as activators.93,94  However, reports from other groups have cast doubt on 
these observations.95,96  It should be noted that a mechanism has recently been 
reported that could possibly explain the apparently paradoxical functions of the 
Cip/Kip proteins.97  The study showed that phosphorylation of p27 by the 
oncogenic tyrosine kinase, BCR-ABL, on a tyrosine residue (Tyr88) that is  
 10 
 
 
 
 
Figure 1.3 The Cip/Kip proteins regulate the activity of a broad range of 
Cdk/cyclin complexes. 
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inserted into the ATP binding pocket during Cdk inhibition, ejects the tyrosine out 
of the active site, consequently relieving inhibition of kinase activity.  The authors 
propose that this mechanism also takes place in the interaction of p27 and 
Cdk4/Cdk6 thereby explaining the seemingly paradoxical functions of p27. 
 The first member of the Cip/Kip family to be identified was p21.  p21 
inhibits cell proliferation in response to genomic insults and is up-regulated in 
irradiated cells and in cells exposed to DNA damaging drugs.  The up-regulation 
of p21 is mediated by p53.98,99  In contrast to p21, p27 expression is induced by 
diverse differentiation and anti-mitogenic stimuli including, transforming growth 
factor-β (TGF-β),80,100 rapamycin,101 contact inhibition,80 depletion of growth 
factors,102 and loss of cell anchorage.103 
 The structure of p27 bound to Cdk2/cyclin A provides detailed insights into 
the molecular basis of Cdk inhibition by the Cip/Kip proteins.104  The KID 
fragment of p27 was used to prepare the ternary complex.  Figure 1.4 shows the 
structure of the p27-KID/Cdk2/cyclin A complex (PDB accession number, 1JSU).  
In the complex, p27-KID folds into an extended, non-globular structure consisting 
of (from N to C terminus): an extended segment, an amphipathic α-helix, an 
amphipathic β-hairpin, a β-strand and a 310 helix.  The extended segment 
(domain D1) binds to the cyclin A subunit of the kinase complex, the amphipathic 
α-helix (domain LH) links the cyclin binding segment to the Cdk binding segment 
(domain D2) which is comprised of the amphipathic β-hairpin, the β-strand, and 
the 310 helix.  The extended segment binds to the conserved substrate binding 
site on the cyclin A subunit.  The amphipathic α-helix does not make a significant 
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Figure 1.4 The structure of the p27/Cdk2/cyclin A complex (PDB; 1JSU).  
p27 binds to the Cdk2/cyclin A complex over an extended surface spanning from 
the cyclin A to the Cdk2 subunit.  Binding to cyclin A prevents substrate binding 
and the binding of the 310 helix of p27 into the ATP binding pocket impedes ATP 
binding.  
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number of contacts with the kinase complex.  The extended structure of the  
p27-KID enables it to interact with the Cdk2/cyclin A complex over a large 
surface area (a total buried surface area of 5,752 Å2).  Most of the hydrophobic 
residues on p27-KID pack against the Cdk2 and cyclin A subunits.  From this 
structure, the binding of p27-KID inhibits the Cdk kinase activity in three ways.  
First, the binding of p27-KID to the substrate binding site on the cyclin obstructs 
the docking of Cdk2 substrates. Secondly, p27-KID binding deforms the catalytic 
cleft on the Cdk2.  This is caused by interactions between p27-KID and an 
amino-terminal β-sheet of Cdk2.  Finally, the 310 helix of p27-KID is inserted into 
the catalytic cleft preventing ATP binding.104  This model of inhibition has been 
extended to p21 and p57 since the three proteins have very similar primary 
structures. 
 
1.3 p27 kinase inhibitory protein 1 (p27kip1) 
 Human p27 is comprised of 198 amino acids and, in addition to cell cycle 
regulation, has been implicated in regulating differentiation,105,106 and more 
recently the control of cell motility.107  p27 is up-regulated in serum-starved and 
contact inhibited cell cultures resulting in cell cycle exit (quiescence).  
Suppression of p27 expression using anti-sense mRNA abrogates cell cycle 
exit.108  When quiescent cultures are supplemented with mitogens, p27 is 
eliminated from cells and the cells re-enter the cell cycle.109  However, quiescent 
cells do not re-enter the cell cycle, even in the presence of mitogens, when the 
elimination of p27 is blocked by treatment with cyclic adenosine monophosphate 
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(cAMP) analogs, rapamycin, or hypoxia.101,110,111  These results demonstrate that 
p27 is a downstream effector of anti-mitogenic signals.112  The in vivo effects of 
p27 deficiency have been investigated using knock-out mice.  Mice lacking p27, 
though viable, exhibit hyperplasia in multiple organs and gigantism with respect 
to their wild-type counterparts.113-115  As a negative regulator of cell cycle 
progression, p27 is an oncosuppressive protein.  Circumvention of p27 cell cycle 
control has been linked to a myriad of human malignancies.  The loss of function 
in most tumor suppressor genes is usually a consequence of deletion of one or 
both alleles of the gene(s).  However, the p27 gene is rarely deleted in human 
cancers.  Mouse model studies have shown that p27 is a haploinsufficient tumor 
suppressor.116  Mice with a single allele of the p27 gene have an intermediate 
frequency of tumor formation relative to their wild-type and null 
counterparts.116,117 
  
1.4 p27 and cancer     
 One of the hallmarks of many types of cancer is the reduced level of p27 
protein relative to normal cells.  However, this reduction in p27 protein levels 
does not stem from p27 gene mutations.118  In fact, germline mutations in the p27 
gene are very rare.119-121  Studies of breast carcinoma have revealed that 
decreased p27 protein levels promote tumor progression and are associated with 
poor prognosis.122-124  The same has also been observed in colorectal,125 lung 
non-small cell,126 gastrointestinal,127 prostrate,128 oral cavity,129 and ovarian 
carcinomas.130  In most of these cancers, the p27 mRNA transcript is expressed  
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at a normal level indicating that the low level of p27 protein is caused by protein 
degradation.  There are two main ways by which tumor cells evade cell cycle 
regulation by p27: (i) degradation of p27 at an accelerated rate (cause of reduced 
p27 protein level)131-133 and (ii) sequestration of p27 in the cytoplasm preventing 
it from inhibiting the nuclear-localized Cdk’s.134  Like many other cell cycle 
regulatory proteins, degradation is one of the main ways by which cells regulate 
p27 levels.  The degradation of p27 is controlled in two ways: cytoplasmic 
ubiquitination by the KPC (Kip1 ubiquitination promoting) complex 135 and nuclear 
ubiquitination by the SCFskp2 complex.136,137,138  The two complexes chemically 
ligate poly-ubiquitin chains to lysine residues on p27.  Prior to being poly-
ubiquitinated by the KPC and SCFskp2 complexes, p27 must be phosphorylated 
on Ser10 and Thr 187, respectively.  After ubiquitination, p27 is degraded by the 
26S proteosome.139  To be recognized by the SCF complex, p27 has to be in 
complex with either Cdk2/cyclin A or Cdk2/cyclin E.140,141  In most malignancies, 
there are increased levels of the skp2 protein leading to accelerated degradation 
of p27.142-145  Table 1.2 shows different types of cancer and the alterations in the 
p27 protein.  It has also been reported that reduced expression of p27 plays a 
role in cancer drug resistance.  Resistance to docetaxel, one of the most 
effective chemotherapeutic agents used in breast cancer treatment, has been 
related to reduced expression of p27.146  It is therefore not surprising that 
designing small molecule inhibitors that mimic p27 inhibitory activity has 
generated a lot of interest.   
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Table 1.2 Alteration of the p27 protein in human malignancies. 
 
 
Malignancy Alteration in p27 protein 
Breast cancer Accelerated degradation147 
Cytoplasmic localization148 
Prostate cancer Accelerated degradation149 
Cytoplasmic localization150 
Ovarian cancer Accelerated degradation151 
Cytoplasmic localization152 
Colorectal cancer Accelerated degradation153 
Non-small cell lung cancer Accelerated degradation145 
Glioma Accelerated degradation154 
Lymphoma Accelerated degradation155 
Chronic myelogenous leukemia (CML) Accelerated degradation133 
Liver cancer Accelarated degradation156 
Cytoplasmic localization157 
Oral squamous cell carcinoma Accelerated degradation143 
 
 
 17 
1.5 p27 is an intrinsically unstructured protein 
 The classical structure-function paradigm postulates that proteins must be 
folded into distinct three-dimensional conformations in order to function.  
However, there is now sufficient evidence that supports the existence of 
functional proteins and protein domains that are intrinsically disordered under 
physiological conditions.158-165  As used herein, intrinsic disorder of a protein or 
protein domain means that under physiological conditions: (i) the isolated protein 
or protein domain lacks tertiary structure; (ii) there are no significant, long-range 
interactions between its residues; and (iii) it exists as an ensemble of many 
highly dynamic conformations.  Intrinsic disorder in proteins is either classified as 
global (disorder of the entire protein), or local (disorder of a protein domain).  
Proteins that exhibit native structural disorder belong to a fast growing family of 
proteins referred to either as intrinsically unstructured proteins (IUP’s), 
intrinsically disordered proteins (IDP’s), natively unstructured proteins (NUP’s), or 
natively disordered proteins (NDP’s).  For the purposes of this dissertation, I will 
use the term intrinsically unstructured proteins (IUP’s).  It is now estimated that 
about one third of the human genome is comprised of sequences that encode 
proteins that have local or global intrinsic structural disorder.  Further analyses 
have shown that the prevalence of IUP’s in a particular species varies directly in 
proportion with its genomic complexity.166  The IUP’s are involved in key cellular  
processes including, but not limited to, DNA recognition (DNA binding domains of 
the GCN4 and NFATC1),167-170 transcriptional activation (kinase-inducible 
activation domain of CREB, activation domains of p53 and VP16),171-175 RNA 
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recognition (RNA recognition segments of HIV-1 Rev and BIV Tat proteins),176-179 
translation (eIF4E binding segment of eIF4G),180 microtubule and actin dynamics 
(caldesmon, thymosin, stathmin/RB3),181-183  and cell cycle regulation (p21, p27, 
p57).  Table 1.3 shows a list of some IUP’s and their biological functions.  IUP’s 
have unique properties that distinguish them from globular proteins. 
 Relative to globular proteins, the primary structures of IUP’s are 
characterized by low sequence complexity and compositional bias.184  They are 
enriched in amino acids that promote structural disorder such as Ser, Ala, Gly, 
Arg, Gln, Pro, Glu, and Lys, and relative to globular proteins, exhibit reduced 
levels of residues that promote structural order such as Trp, Cys, Phe, Ile, Asn, 
Val, Tyr, and Leu.184,164  Globular proteins typically have a comparatively larger 
number of order promoting hydrophobic amino acids that form their cores and 
facilitate folding.  Bioinformatics programs that predict structural disorder based 
on the amino acid attributes of the IUP’s with a high degree of accuracy have 
been developed.  Examples include PONDR,185 DISOPRED,186 and 
GLOBPLOT.187  The sequence properties of IUP’s indicate that their intrinsic 
disorder is encoded in their primary structures as is the case for the secondary 
and tertiary structures of globular proteins.  Due their intrinsic disorder, IUP’s 
often exhibit extended conformations and have larger hydrodynamic radii relative 
to globular proteins of comparable mass.163  Because of their extended 
structures, IUP’s are sensitive to proteolytic cleavage.188  In addition, IUP’s are 
heat stable,81 have high net charge,163 and low mean hydrophobicity.163  The 
disordered structures of IUP’s have been characterized using X-ray 
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Table 1.3 Biological functions of IUP’s. 
 
 
Protein Function 
Naked2189 Vesicle transport 
Bim, Bad, BMF190 Apoptosis 
C-terminal domain of CtBP191 Nuclear transcriptional co-repression, 
golgi membrane tubule fusion 
C-terminal domain of the measles virus 
nucleoprotein159,192 
Measles virus RNA synthesis 
Thymosin-β193 Actin dynamics 
Acidic activation domain of NF-κB194 Transcriptional activation 
Basic DNA-binding region of the 
leucine zipper protein GCN4167 
Transcriptional activation 
Amino-terminal domain of p53173 Onco-suppressing transcription factor 
CITED2195 Hypoxic response 
High mobility group (HMG) domain, of 
LEF-1196 
Regulation of the T-cell receptor-a 
gene enhancer 
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crystallography, nuclear magnetic resonance (NMR), circular dichroism (CD) 
spectroscopy, raman optical activity spectroscopy (ROA), fourier-transformed 
infra-red spectroscopy (FTIR), analytical ultracentrifugation (AUC), dynamic light 
scattering (DLS), small angle X-ray scattering (SAXS), and fluorescence 
spectroscopy.  Although IUP’s have disordered structures prior to binding their 
targets, NMR and CD studies have demonstrated that some IUP’s have 
segments that exhibit a natural propensity for nascent secondary 
structures.197,198,188,199  One key property of most IUP’s is that they fold on 
binding their targets and become ordered.197,175,200  This folding-on-binding 
phenomenon was manifested in the interaction of p27 and Cdk2/cyclin A 
complex.197 
 p27 is a globally unstructured IUP with segments that exhibit nascent 
secondary structure.  Of the three Cip/Kip proteins, p27 is the best characterized 
structurally because it can be expressed at high levels in E. coli, can be purified 
to homogeneity, and is highly soluble.  p27 exhibits many characteristics of 
IUP’s.  Consistent with the properties of IUP’s, full-length p27 migrates at about 
27 kDa during a sodium dodecyl sulfate polyacrylamide gel electrophoresis (the 
calculated molecular weight of p27 is 22 kDa) indicating that it is a highly 
extended polypeptide with a large hydrodynamic radius.80  Moreover, analysis of 
p27 by limited proteolysis shows that free p27 is very susceptible to cleavage.201  
However, when p27 interacts with the Cdk2/cyclin A complex, it is refractory to 
proteolysis.201  The secondary structures of p27, p21 and p57 determined by CD 
at low concentrations are strikingly similar.188,198,202  The three proteins are 
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largely unstructured with a low population of helical secondary structure.  The CD 
spectra show that the native structural disorder of the Cip/Kip proteins is well 
conserved.  It should be noted that the results on secondary structure discussed 
above are derived from studies of KID constructs and not the full-length proteins.   
Like the KID’s, the full-length proteins are also largely unstructured.  NMR 
analysis shows that full-length p27 and p27-KID have very similar secondary 
structures.197  The conservation of the disordered structures of the Cip/Kip 
proteins argues strongly that structural disorder plays a significant role biological 
function.  p27 folds dramatically on binding the Cdk2/cyclin A complex and 
attains structural order as shown in Figure 1.4, above.  The plasticity of the 
structure of p27 and its template driven folding on binding enables p27 to interact 
with a broad range of Cdk complexes.203  The folding on binding mechanism 
affords high specificity but at a great entropic cost.  It therefore follows that the 
thermodynamic contributions of the binding-on-folding process due to enthalpy 
and entropy have to be appropriately balanced so that binding occurs 
spontaneously.   
 
1.6 Thermodynamics of the association of p27 and Cdk2/cyclin A 
 The KID’s of the Cip/Kip proteins are comprised of three domains: (i) a 
cyclin-binding domain (hereafter referred to as D1); a linker domain (hereafter 
referred to as LH); and (iii) a Cdk binding domain (hereafter referred to as D2).  
D1 has a motif that binds to the substrate binding site on the cyclin subunit that is 
comprised of Leu32, Phe33, and Gly34.  These three residues are conserved 
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amongst the Cip/Kip proteins.  On D2, one key residue is Tyr88 which is inserted 
into the ATP binding pocket when p27 interacts with the Cdk2/cyclin A complex.  
Tyr88 is part of the 310 helix of p27 that was discussed in Section 1.2.  Figure 1.5 
shows a sequence alignment of the KID’s of members of the Cip/Kip family.  The 
sequences D1 and D2 are well conserved amongst the three family members, 
but the sequence of domain LH is not conserved.  Only 3 of the 22 residues in 
this domain are conserved.  The number of residues in domain LH, 22, is the 
same for all the Cip/Kip proteins.  As discussed above, the secondary structures 
of the Cip/Kip proteins are mainly unstructured with nascent helical properties.  
Nuclear magnetic resonance (NMR) 13C-alpha (13Cα) chemical shift analysis 
showed that D1 and D2 are largely unstructured and the nascent helical structure 
observed using CD is localized in the LH domain.197  The nascent helical 
structure of the linker domain is conserved amongst all three members of the 
family.188,198,202  This sequence divergence/structure conservation relationship is 
atypical since the domains whose sequences are conserved, D1 and D2, are 
unstructured, and the domain whose sequence is poorly conserved, LH, exhibits 
conserved structural features. 
 Thermodynamically, the folding of p27 on binding the Cdk2/cyclin A is very 
unfavorable since it requires a large negative entropy change.  Lacy, et al., 
demonstrated that this large negative entropic cost is overcome by the quantity of 
heat (enthalpy associated with binding, ∆H) released during the extensive folding 
of p27 on binding to Cdk2/cyclin A.197  This results in a negative Gibbs free 
energy change (∆G) for binding and spontaneous binding.  The interaction of p27  
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Figure 1.5 Sequence alignment of the KID domains of the Cip/Kip proteins.     
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and the Cdk2/cyclin A complex is therefore an enthalpically driven process.  The 
heat capacity change associated with binding (∆Cp) was found to be large and 
negative, and comparable to values obtained from protein folding events.  The 
large negative heat capacity change is an indicator of the extent to which 
hydrophobic interactions contribute to the formation of the ternary complex.204,205  
Lacy, et al, further demonstrated that the interaction of p27 with the Cdk2/cyclin 
A complex is more favorable than the interaction of p27 with either cyclin A or 
Cdk2 alone.  The binding of p27 to the Cdk2/cyclin A complex is sequential, with  
p27 binding to the cyclin A subunit first, followed by folding of the linker domain, 
and finally the folding of D2 into a β-hairpin, a β-strand and a 310 helix.  The 
kinetics of association and dissociation of p27 and cyclin A are much faster 
relative to those of p27 and Cdk2.  While the functions of D1 and D2 are well 
characterized, the role of domain LH is not well understood.  Is it just a spacer 
between D1 and D2 or does it play a role in the binding process?  If so, why does 
it have a conserved structure?    
 
1.7 Project hypotheses and strategy   
 To understand the role of the linker domain of p27, I first investigated the 
interactions of D1 and D2 with P-Cdk2/cyclin A (a mutant with the linker domain 
deleted).  Given the structural conservation of the linker domain of p27, I 
hypothesize that linker domain is necessary for the interaction of p27 and the  
P-Cdk2/cyclin A complex and for p27 to perform its biological function. 
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 Although the sequence of domain LH is not conserved amongst 
members of the Cip/Kip protein family, it is very highly conserved for each protein 
in different species.  Figure 1.6 shows an alignment of the sequences of p27 LH 
domains in different species.  In mammals (from mouse to man – a period of over 
100 million years in the evolutionary timeline), the sequence of the p27 linker 
domain is 100% conserved and has resisted selective pressure.   This indicates 
that the sequence of each individual protein may be significant in determining its 
functional properties.  Otherwise, there would have been no reason for these 
sequences to be selected for and to persist during evolution.  However, the 
evolutionary stability of these sequences raises a question as to whether it is the 
sequence or the structure of the LH domain that is important in determining the 
biophysical and functional properties of these proteins.  To answer this question, 
I designed p27-KID mutants in which the LH domain of p27 was replaced with 
the LH domains of either p21 (p27-KIDp21helix) or p57 (p27-KIDp57helix) and studied 
their interaction with the Cdk2/cyclin A complex.  These mutants are hereafter 
referred to as the chimeric mutants.  Since D1 and D2 are well conserved in the 
three proteins, the chimeric mutants should be suitable for studying the 
sequence-divergence/structure-conservation relationship of the linker domains of 
the three Cip/Kip proteins.  I hypothesize that if the structure of the LH domain is 
the dominant determinant of the biophysical and functional properties of the 
Cip/Kip proteins on interacting with the Cdk2/cyclin A complex, then the 
properties of the p27-KIDwt relative to the chimeric mutants would be very similar 
(recall that amongst the Cip/Kip proteins, the structures are conserved but the 
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Frog        HDELRSELKRQLKEIQASDCQR 32 
Pig         HEELTRDLEKHCRDMEEASQRK 37 
Cat         HEELTRDLEKHCRDMEEASQRK 37 
Mink        HEELTRDLEKHRRDMEEASQRK 37 
Human       HEELTRDLEKHCRDMEEASQRK 37 
Hampster    HEELTRDLEKHCRDMEEASQRK 37 
Rat         HEELTRDLEKHCRDMEEASQRK 37 
Mouse       HEELTRDLEKHCRDMEEASQRK 37 
Chickhen    HEELNRDLKKHRKEMEEACQRK 37 
Zebrafish   HEELKKDFQRQLRTMEDASAEA 37 
 
Figure 1.6 Alignment of p27-LH domains from different species.  The 
sequences of LH domains from mammals are circumscribed in the red box. 
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sequences are different).  On the other hand, if the sequence of the LH domain is 
the dominant determinant of the properties of the interaction between the Cip/Kip 
proteins and P-Cdk2/cyclin A, then the properties of the interaction of the 
chimeric mutants with P-Cdk2/cyclin A relative to p27-KIDwt would be different.  
In addition to the sequence-structure relationship of the linker domains of the 
Cip/Kip proteins, I also studied the role of the three conserved residues in 
domain LH by mutating the residues to glycines (Glu39Gly/Leu41Gly/Arg43Gly, 
the p27-KID∆C mutant) and probed the interaction of this mutant with the P-
Cdk2/cyclin A complex. 
 Many IUP’s exhibit a small amount of nascent helical secondary structure 
in the absence of their binding partners.  The polypeptide segments giving rise to 
these features typically fold into α-helices upon binding their biological targets.  I 
propose that one of the roles of the nascent helical structures is to attenuate the 
entropic cost associated with the folding-on-binding process.  I further 
hypothesize that increasing the helical content of the linker domain would 
decrease the entropic cost associated with the folding on binding and thereby 
decrease the Gibbs free energy of interaction of the p27-KID and a Cdk/cyclin 
complex.  Conversely, decreasing the helical content would increase the entropic 
cost and make the reaction less favorable.  One underlying assumption of these 
hypotheses is that all the mutants fold in exactly the same way as the wild-type 
protein.  To test these hypotheses, p27-KID mutants which have LH domains that 
are either more (p27-KID+H) or less (p27-KID-H) helical relative to the wild-type 
p27-KID (p27-KIDwt) were designed and their thermodynamic and functional 
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properties on binding to the Cdk2/cyclin A complex probed.  In addition, I also 
designed a mutant in which the LH domain of p27 was replaced with a flexible 
loop, 22 residues long, and performed similar studies.  
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Chapter 2: Materials and methods 
 
2.1 Design of the more and less helical p27-KID linker domain mutants 
 My approach of designing  p27-KID mutants with linker domains that were 
either more or less helical than the wild-type p27-KID was to substitute solvent 
exposed residues within the linker domain with residues that are known to either 
stabilize or destabilize helices.  Mutating the solvent exposed residues minimizes 
disruption of contacts between p27 and the Cdk2/cyclin A complex.  This reduces 
the possibility that the results obtained from the succeeding studies are a 
consequence of the disruption of contacts between p27 and Cdk2/cyclin A.  The 
solvent accessible surface area (SASA) for each residue within the linker domain 
was analyzed using the GETAREA program.206  The input used for the program 
was the pdb file of the p27-KID/Cdk2/cyclin A complex (1JSU).  Residues that 
had more than 50% of their total surface area exposed to solvent were selected 
as suitable candidates for mutagenesis.  From the output, 10 residues had more 
than 50% of their surface areas exposed (Table 2.1).  The 10 candidate residues 
were further analyzed using the Insight II program (Accelrys, San Diego, CA).  
The PDB file, 1JSU, was used as an input and all the atoms within a 6 Å radius 
of every atom of each candidate residue were analyzed.  This was done to 
determine whether any of the candidate residues interacted with the residues of 
the binary complex.  No close contacts were observed for the 10 candidate 
residues.  After this analysis, all the 10 candidate residues were determined to be 
suitable for mutagenesis.  Figure 2.1 shows the orientation of the side chains of  
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Table 2.1 Solvent exposure of the residues in the linker domain of p27. 
 
 
Residue Percentage of surface area exposed to solvent 
His38 40.9 
Glu39 84.1 
Glu40 79.9 
Leu41 1.9 
Thr42 22.7 
Arg43 56.7 
Asp44 33 
Leu45 0.4 
Glu46 26.9 
Lys47 76.2 
His48 27.2 
Cys49 13.2 
Arg50 67.1 
Asp51 55.4 
Met52 20.2 
Glu53 37.9 
Glu54 81.6 
Ala55 87.1 
Ser56 14.6 
Gln57 30 
Arg58 81.3 
Lys59 56.1 
 
 
The residues selected for mutagenesis are in bold font. 
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Figure 2.1 The structure of p27/Cdk2/cyclin A (PDB; 1JSU) showing the 
residues determined to be suitable for mutagenesis.  The residues are 
colored red for acidic residues, blue for basic residues, and green for 
hydrophobic residues.  Cdk2 is colored orange and cyclin A cyan. 
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the selected residues in the structure of the p27/Cdk2/cyclin A structure (PDB; 
1JSU). 
 The stability an α-helix is determined both by the helix forming propensity 
of the amino acids in its primary structure and the interactions between side 
chains.207  Two different strategies were used in the design of mutants with 
stabilized linker domains.  In the first approach, alanine was used as a possible 
stabilizer of the helical structure of the linker domain.  Two alanine mutants were 
designed.  In the first alanine mutant, all the residues that were selected for 
mutagenesis were substituted with alanines.  Alanine was chosen because 
previous studies have shown that alanines stabilize and have a high propensity 
to occur in α-helices.208-210  This mutant, in which the 10 candidate residues were 
substituted with alanines, was designated p27-KIDA10.  In the second alanine 
mutant, all the 22 residues in the linker domain were substituted with alanines.  
This mutant was designated p27-KIDA22.  In the second approach, leucine was 
used as a potential stabilizer of the linker domain helix.  Like alanine, leucine has 
also been shown to stabilize and have a high propensity to occur in  
α-helices.207,209  Hydrophobic interactions between leucine side chains on one 
face of an α-helix shield the backbone amides and carboxyl groups from 
hydrogen bonding with water, thus stabilizing the helical conformation.211  One 
disadvantage of leucine, however, is its hydrophobic nature.  To counter the 
hydrophobicity of leucine, I designed a library of mutants in which the number of 
leucines replacing the candidate residues was balanced with charged, polar 
residues.  The substituted residues in these mutants consisted of either 7 
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leucines and 3 polar residues, 6 leucines and 4 polar residues, 5 leucines and 5 
polar residues, etc.  I also ensured that the polar residues had a high helical 
propensity.  The leucines were strategically positioned three and four residues 
apart in the helix.  Past studies have shown that leucines positioned three and 
four residues apart stabilize α-helices.212  In addition, leucines positioned four 
residues apart is one of the most commonly observed pairwise side chain 
interactions in protein α-helices.213  A total of 6 mutants were designed.  The 
mutants were designated p27-KIDSL1 (SL1; stabilized by leucine, construct 1), 
p27-KIDSL2, p27-KIDSL3 (p27-KID+H), p27-KIDSL4, p27-KIDSL5, and p27-KIDSL6.  In 
the p27-KIDSL6 mutant, all the candidate residues were substituted with leucines.  
This mutant was designed to test if charged residues that were determined to be 
unsuitable for mutagenesis could counter the hydrophobicity of the 10 leucines.   
 For the less helical mutant, the candidate residues were replaced with 
glutamate (Glu) residues.  The premise behind choosing Glu residues is that 
electrostatic repulsion between the negatively charged Glu side-chains should 
destabilize the helix backbone.214  In addition, the substituting residues close to 
the carboxy terminus of the helix with Glu residues would result in further 
destabilization of the helix due to repulsion of the negatively charged Glu  
side-chain and the negative carboxy-terminus helix dipole.215  Another advantage 
of using glutamate is that the polar Glu side-chain should enhance the solubility 
of this mutant.  This mutant was designated p27-KID-H. 
 A mutant with a flexible loop comprised of mainly glycines, a known helix 
breaker, and other residues with a low propensity for being in α-helices was also 
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designed.  The residues that comprised this mutant were chosen with an 
objective of minimizing helical secondary structure in the linker domain.  The 
number of residues in the loop equaled 22, as in the p27 linker domain.  This 
mutant was designated p27-KIDloop.  Table 2.2 shows the linker domain 
sequences of all the mutants designed.  
 
2.2 Preparation of mutagenesis cassettes 
 The p27-KID linker domain mutants were cloned by cassette mutagenesis.  
First, the deoxyribonucleic acid (DNA) sequence encoding residues 22-71 of p27 
(including the cyclin binding domain, the linker domain, and the Cdk binding 
domain up to E71) was determined.  The bases encoding the wild-type p27 linker 
domain residues were changed such that they encoded the linker domain 
sequences of the mutants.  Oligonucletides used in the preparation of the 
mutagenesis cassettes were then designed.  For each mutant, a forward and 
reverse oligonucleotide, each 104 bases long, with 40 overlapping 
complementary bases and end primers for each oligonucleotide, were designed.  
The sequences of the oligonucleotides used for the preparation of the 
mutagenesis cassettes are shown on Table A.1.  End primers with the 
sequences 5’ GTAACGCATATGGAGCACCCCAAGCCCTCGGCC 3’ and 5’ 
CCCCGCCTCGAGGGGTTTGTGATTCTGAAAATCGA 3’ were designed for the 
p27-KIDp21helix and p27-KIDp57helix mutants.  The sequences for the end primers 
designed for the other mutants were: 5’ GCCTCCCATATGGAGCAC-CCCAAG 3’ 
and 5’ CTTGGGCTCGAGGGGTTTGTGATTC 3’.  Included in the  
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Table 2.2 Linker domain sequences for the p27-KID variants designed to be 
more and less helical. 
 
 
Variant Sequence of linker domain 
p27-KIDwt HEELTRDLEKHCRDMEEASQRKa 
p27-KIDA10 HAALTADLEAHCAAMEAASQAAb 
p27-KIDA22 AAAAAAAAAAAAAAAAAAAAAAb 
p27-KIDSL1 HLELTLDLELHCLLMELLSQRKb 
p27-KIDSL2 HEELTLDLELHCLLMELLSQRKb 
p27-KIDSL3(p27-KID+H) HEELTKDLELHCLLMELLSQRKb 
p27-KIDSL4 HEELTKDLELHCKLMEELSQKKb 
p27-KIDSL5 HLELTLDLEEHCLKMELESQLKb 
p27-KIDSL6 HLLLTLDLELHCLLMELASQLLb 
p27-KID-H HEELTEDLEEHCEEMEEESQEEb 
p27-KIDloop TNPGNGGHGGTGVGGNGGNGHGb 
 
 
a
 The residues determined to be suitable for mutagenesis are underlined and are 
in bold font in the linker domain sequence of the wild-type p27-KID (p27-KIDwt). 
b
 The mutated residues are underlined. 
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oligonucleotide design, were a 5’ NdeI restriction site and a 3’ XhoI restriction site 
for all the mutants.  The mutagenesis cassettes were prepared by overlap 
extension polymerase chain reaction (oePCR).  The overalap extension 
polymerase chain reaction is illustrated in Figure A.1.  First, the single stranded 
non-overlapped ends of the long oligonucleotides are filled in by a proofreading 
polymerase (Expand high fidelity polymerase, Roche, Mannhein, Germany) to 
yield a double stranded DNA cassette.  However, this double stranded DNA 
cassette product is in low quantities since only a small amount (10 ng) is added 
to the reaction.  In the succeeding cycles, the end primers, which are present in 
large quantities in the reaction (125 ng), amplify the double stranded DNA 
cassettes.  The details of the oePCR reaction that I performed including 
concentrations of reactants, and thermocycler settings are reported in Table A.2 
and Table A.3.  Figure 2.2 shows the product from the oePCR reaction for the 
preparation of the mutagenesis cassette for the p27-KID-H mutant.  Similar 
product quantities were obtained for the other mutants. 
 
2.3 Preparation of cassettes for cloning Cip/Kip linker domain peptides 
 Overlap extension PCR was also used in the preparation of 
oligonucleotide cassettes that were used to prepare expression plasmids for 
Cip/Kip linker domain peptides.  For the preparation of each peptide cassette, 
two long oligonucleotides (98 bases each; 37 overlapping complementary bases) 
were designed and end primers were designed.  Table A.4 shows the sequences 
of the oligonucleotides and end primers that were designed for each linker  
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Figure 2.2 Agarose gel analysis of the oePCR for the p27-KID-H mutant.  The 
descriptions of the lanes are as follows: (a) PCR markers, (b) No primer control, 
(c) No enzyme control, (d) No template control, and (e) p27-KID-H oePCR.  The 
expected size of the p27-KID-H oePCR product is 168 bp. 
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domain peptide.  The cassette design for each peptide included (in the 5’ to 3’ 
direction with respect to the coding strand): (i) a 5’ SacII restriction enzyme site, 
(ii) bases encoding a 6-histidine (His) tag, a thrombin cleavage site, the linker 
domain sequence, and a stop codon, and (iii) a 3’ EcoRI restriction site.  The 
Cip/Kip linker domain sequences designed included a Trp residue after the 22nd 
residue of the linker domain to facilitate protein concentration determination since 
these peptides otherwise lack chromophores that absorb light near 280 nm.  It 
should be noted that there is a conserved Trp at the end of the Cip/Kip linker 
domain sequences (corresponding to Trp60 of p27).  The cloning cassette for 
each peptide was produced in high yield using this procedure.  The oePCR 
product for the p27 linker domain peptide is shown on Figure A.2.  The 
concentrations of the reagents and the thermocycler settings were the same as 
in Section 2.2 above. 
 
2.4 Preparation of Escherichia coli expression plasmids  
 The pET28a (+) plasmid (Novagen, San Diego, CA) was used as the 
starting vector to construct plasmids for p27 protein expression in Escherichia 
coli (E.coli).  The multi-cloning site of the pET28 vector is shown on Figure 2.3.  
Three sets of plasmids were prepared.   
The first set of plasmids prepared was used for cloning the Cip/Kip linker 
domain peptides.  The starting plasmid was the pET28 vector.  A cassette 
encoding a glutathione S-transferase tag with 5’ NcoI site and 3’ EcoRI restriction 
sites was cloned between the NcoI and EcoRI restriction sites.  It should be  
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Figure 2.3. The muticloning site of the pET28 vector.  The key restriction sites 
are boxed in rectangles. 
 
 
 
 
 
T7 promoter 
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noted that there is a SacII site that was engineered into the cassette between the 
end of the GST sequence and the EcoRI site.  The cassettes for the Cip/Kip 
linker domain peptides prepared in Section 2.3 were digested with SacII and 
NdeI and cloned into the vector.  As mentioned in Section 2.3 above, the Cip/Kip 
linker domain peptides have a His tag at their 5’ ends after the SacII restriction 
site.  The plasmids formed after ligation of the Cip/Kip linker domain cassettes 
into the pET28-GST-His vector therefore have both GST and His tags.  This 
vector is hereafter referred to as the pET28-GST-His vector.  Cip/Kip linker 
domain peptides with both GST and His tags have two advantages.  First, it 
provides more purification options.  In addition, the use of a GST-His tag makes 
the fusion protein large enough to be visualized using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).  Without the large GST tag, the 
small peptides (about 3.3 kDa each) would easily diffuse out of standard 
concentration polyacrylamide gels.  Figure 2.4 shows a diagram of the  
pET28-GST-His vector used to express the p27 linker domain peptide.   
 The second set of plasmids prepared was used to express the p27-KID 
mutants.  A pET28 plasmid with p27-KID cloned between the NdeI and EcoRI 
sites had previously been prepared in the laboratory.197  The sequence of the 
p27-KID coding region is shown on Figure A.3.  The XhoI site that follows the 
EcoRI site in the pET28 vector was mutated to prevent restriction by the XhoI 
enzyme.  Within the p27 Cdk binding domain (D2) sequence, the bases encoding 
Leu70 and Glu71 were mutated from CTAGAG to CTGGAG (the XhoI site).  The 
cassettes of the p27-KID mutants prepared in Section 2.2 were then digested  
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Figure 2.4 The pET28-GST-His p27-LH vector construct. 
 
 
 
 
 
 
 
 
 
N-terminal C-terminal 
Thrombin cleavage site 
 42 
with NdeI and XhoI restriction enzymes and ligated into the pET28-p27-KID 
vector with the engineered XhoI site.  Some of the cassettes for the p27-KID 
mutants were ligated into the pET28-GST-His vector.  A cassette coding for  
p27-KID was amplified from the pET28p27-KID vector by PCR using the 
following primers:  5’ GCGGCCTGGTGCCGCGCGGCAGCCAT 3’ and 5’ 
CTTGTCGACG-GAGCTCGAATTCGGA 3’.  The cassette and the  
pET28-GST-His-p27-LH plasmid were both digested using NdeI and EcoRI 
enzymes followed by ligating the p27-KID cassette into the digested  
pET28-GST-His vector.  This plasmid was termed pET28-GST-Hisp27-KID.  The 
cassettes for the p27-KID mutants were ligated into the p27-KID coding region of 
the pET28-GST-Hisp27-KID by cassette mutagenesis in the same way that they 
were cloned into the pET28p27-KID plasmid.  Table A.5 shows the p27-KID 
mutants and the plasmids that they were cloned into.  Figure 2.5 shows a 
schematic diagram of the cassette mutagenesis design. 
 The last set of plasmids prepared was used for ligating mutants into a 
pET28vector with the full-length p27 (flp27) cloned between the NdeI and EcoRI 
sites.  The sequence of the flp27 coding region of this vector is shown in Figure 
A.4.  The DNA sequence encoding flp27 has a PstI restriction site (CTGCAG) 
within the bases coding for Ala28, Cys29, and Arg30 (GCCTGCAGG).  These 
residues are located in the cyclin binding domain (D1) of p27.  In addition, bases 
coding for the residues Pro92 and Arg93 constitute a SacII restriction enzyme 
recognition site (CCGCGG).  These residues lie within the Cdk binding domain of 
p27.  The pET28a (+) plasmid does not have PstI or SacII restriction sites.  The  
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Figure 2.5 Schematic diagram of the cassette mutagenesis design.  LH* is a 
mutated cassette of a p27-KID linker domain variant.  The same approach was 
used to clone the mutant cassettes into the pET28p27-KID vector. 
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following primers were used to amplify cassettes from the plasmids in which the 
p27-KID linker domain mutants had been cloned: 5’ GCCCTCGGCCTGCAGGA-
ACCTCTTCGGCCCGG 3’ and 5’ CAGGCACCTTTGGGGGGCCGCGGGGGTC 
3’.  The pET28p27-KIDSL3 (pET28p27-KID+H), pET28-GST-Hisp27-KID-H, and the 
pETGST-Hisp27-KIDloop plasmids used as templates.The cassettes and the 
pET28flp27 vector were digested with PstI and SacII enzymes followed by 
cloning the cassettes into the digested vector. 
 
2.5 Preparation of retroviral shuttle vectors 
 The MSCV-I-GFP vector was the starting plasmid.  A vector map of the 
MSCV-I-GFP vector is shown on Figure A.5.  Cassettes were amplified from the 
pET28flp27wt, pET28flp27SL3 (pET28flp27+H), pET28flp27-H, and the 
pET28flp27loop plasmids prepared in Section 2.4 above using the following 
primers: 5’ GGACCCGAATTCATGTCAAACGTGCGAGTGTCTAACGGGAGCC-
CTAG 3’ and 5’CAGACCGAATTCTTATTACGCATAATCCGGCACATCATACG-
GATACGTTTGACGTCTTCTGAGGCCAGGCTTCTTGGGC 3’.  The primers 
were designed such that the amplified cassettes had EcoRI sites at both the 5’ 
and 3’ ends.  The cassettes were digested with EcoRI and ligated into the 
MSCV-I-GFP vector.  The plasmids were purified using an endonuclease free 
plasmid kit (Qiagen, Valencia, CA) and the sequences of the plasmid constructs 
were confirmed by DNA sequencing.  The sequences of the MSCV-I-GFPflp27wt, 
MSCV-I-GFPflp27SL3 (MSCV-I-GFPflp27+H), MSCV-I-GFPflp27-H, and the  
MSCV-I-GFPflp27loop are shown on Table A.6. 
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2.6 Expression and purification of Cip/Kip linker domain peptides 
 The linker domain peptides were expressed as fusion proteins with amino-
terminal glutathione S-transferase and histidine tags (GST-His).  The fusion 
proteins were expressed in expressed in E. coli BL21 (DE3) cells (Novagen, San 
Diego, CA) at 37 °C in LB media and induced with 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) when the culture reached mid-log phase 
(absorbance at 600 nm (A600) ≈ 0.8).  Cells were allowed to grow for 2 hours 
following induction.  Cells were harvested by centrifugation at 5,000 x g for 10 
minutes at 4 ˚C using a Sorvall Evolution RC centrifuge (Mandel Scientific, 
Ontario, Canada).  The harvested cells were then resuspended in a nickel 
chelating column loading buffer (Ni-A buffer; 20 mM Tris pH 8.0, 500 mM NaCl, 5 
mM imidazole).  Every gram of cell pellet was resuspended in 10 ml of Ni-A 
buffer.  The resuspended cells were lysed by sonication using a Branson sonifier 
450 (Branson, Danbury, CT).  The cell lysate was cleared of cell debris by 
centrifugation at 20,000 x g for 30 minutes at 4 ˚C followed by filtration using a 
0.45 µm Millex syringe filter (Millipore, Bedford, MA).  Unless stated otherwise, 
this procedure was used prepare the soluble extract after protein over-expression 
in E. coli.  The fusion proteins were then purified from the soluble cell extract 
using Ni2+-affinity chromatography using a Hi-Trap nickel chelating column (GE 
Healthcare, Piscataway, NJ).  With the exception of the resin used in the high 
performance liquid chromatography columns, all chromatography resins used for 
protein purification were obtained from GE Healthcare, Piscataway, NJ.  The 
soluble extract was loaded onto the nickel chelating column followed by a two 
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step washing procedure.  In the first step, the column was washed with five 
column volumes of Ni-A buffer.  This was followed by a second wash step in 
which the column was washed with five column volumes of a buffer containing 
90% Ni-A buffer and 10% of nickel column elution buffer (Ni-B; 20 mM Tris pH 
8.0, 500 mM NaCl, 500 mM imidazole).  The fusion protein was eluted from the 
column by washing with a buffer containing 30% Ni-A and 70% Ni-B.  The eluted 
protein fraction was dialyzed against GST-A buffer (140 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4, 5 mM dithiothreitol, pH 7.3) overnight at 4 °C.  
This was followed by glutathione-affinity chromatography.  The protein was 
loaded onto a glutathione affinity column, washed with five column volumes of 
GST-A buffer and eluted from the column by washing with five column volumes 
of GST elution buffer (GST-B buffer; 50 mM Tris pH 8.0, 10 mM reduced 
glutathione, 5 mM dithiothreitol).  The fraction eluted from the glutathione affinity 
column was dialyzed against the high performance liquid chromatography 
sample buffer (Buffer D; 10 mM Tris pH 7.2, 5 mM dithiothreitol).  This was 
followed by thrombin cleavage at 4°C.  Thrombin (No vagen, San Diego, CA) was 
added to the cleavage reaction at a concentration of 0.5 units per milligram of 
fusion protein.  The cleaved protein was then purified using high performance 
liquid chromatography (HPLC).  The cleaved protein was mixed in a 1:1 ratio 
(volume/volume) with the HPLC loading buffer (HPLC-A; 0.1% trifluoroacetic acid 
in water) and loaded onto a C18 column (Vydac, Hesperia, CA).  The protein was 
eluted from the column by increasing the concentration of the HPLC elution 
buffer (HPLC-B; 0.1% trifluoroacetic acid in acetonitrile) at a rate of 1% per 
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minute up to a concentration of 80% HPLC-B.  The HPLC silica-based column 
used here requires use of buffers with salt concentrations lower than 150 mM 
and pH lower than 7.5.  Higher salt and pH conditions are detrimental to the 
performance and longevity of the column.  The fractions were then lypholized 
and analyzed by mass spectrometry.  Figure 2.6 shows the purification of the p27 
linker domain peptide.  Similar results were achieved for the p21 and p57 linker 
domain peptides.  The mass spectrometry analyses of the linker domain peptides 
are shown on Figure 2.7 and Figure 2.8.  
 
2.7 Expression and purification of p27-KID variants 
 The p27-KID linker domain mutants listed in Table A.5 were expressed in 
E.coli as described in Section 2.6.  Like the linker domain peptides, the bacterial 
cells that contained the expressed protein were resuspended in Ni-A buffer.  
After cell lysis and clearing, some of the mutants were found to be insoluble.  
Table A.6 shows all of the p27-KID mutants expressed, their solubilities, and the 
corresponding expression plasmid(s).  Only the mutants with soluble extracts 
were purified.  The soluble extract was loaded onto a Hi-Trap nickel column, 
followed by washing using five column volumes of Ni-A buffer.  Protein was 
eluted from the column by washing with 100% Ni-B buffer.  The eluted protein 
was dialyzed overnight against thrombin cleavage buffer (Buffer T; 20 mM Tris 
pH 8.0, 50 mM NaCl, 5 mM dithiothreitol) at 4 ˚C.  The cleaved protein was 
boiled for 20 minutes and centrifuged at 30, 000 g for 30 minutes at 4 ˚C.  The 
pellet mainly contains heat-denatured E. coli proteins and the supernatant  
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Figure 2.6 Purification of the p27 linker domain peptide (p27-LH). 
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Figure 2.7 Mass spectrometry analyses of p27 and p21 linker domain 
peptides. 
 
p21 linker domain peptide 
 
Expected mass      3080.40 
Observed mass     3082.27 
p27 linker domain peptide 
 
Expected mass      3339.60 
Observed mass     3340.0 
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Figure 2.8 Mass spectrometry analysis of p57 linker domain peptide. 
 
 
 
 
 
 
p57 linker domain peptide 
 
Expected mass      3220.40 
Observed mass     3218.84 
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contains the over-expressed mutant p27 protein.  Figure 2.9 shows the 
purification of the p27-KID-H mutant.  Similar results were achieved in the 
expression of the other p27-KID linker domain mutants.  After purification, the 
secondary structures of the more and less helical p27-KID mutants were 
determined by circular dichroism spectropolarimetry.  For the more helical mutant 
the p27-KIDSL3 was found to exhibit the desired secondary structural properties 
and was chosen for further study.  Hereafter, this mutant is referred to as the 
p27-KID+H.  The p27-KID-H and p27-KIDloop mutants were also found to have the 
desired structural properties.  The p27-KID linker domain mutants that I studied 
in detail include:  p27-KID+H, p27-KID-H, p27-KIDloop, p27-KIDp21helix, p27-
KIDp57helix, and p27-KID∆C.  These mutants were characterized by mass 
spectrometry (Figure 2.10, Figure 2.11, and Figure 2.12) and sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  Figure 2.13 shows the 
SDS-PAGE gels of the purified proteins. 
 The D1 peptide (residues 23-57) was prepared by solid phase peptide 
synthesis (Hartwell Center, St. Jude Children’s Research Hospital, Memphis, 
TN).  A pET28a plasmid encoding a peptide corresponding to the Cdk binding 
domain of p27 (D2; residues 58-105) was used to express a His-tagged D2 
fusion protein.  The D2 peptide was purified using the same protocol as used for 
the KID variants described above (the nickel buffers used in the purification of D2 
were phosphate based, D2-Ni-A and D2-Ni-B, as specified in Section A.1).  After 
purification, the D2 peptide was analyzed by mass spectrometry (Figure 2.14). 
Prior to isothermal titration calorimetry (ITC) experiments, preparation of  
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Figure 2.9 Purification of the p27-KID-H mutant. 
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Figure 2.10 Mass spectrometry analyses of p27-KIDwt and p27-KIDp21helix. 
p27-KIDwt   Expected mass:  10406.6 
                  Observed mass:  10406.5   
p27-KIDp21helix   Expected mass:  10147.3 
                         Observed mass:  10147.9   
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Figure 2.11 Mass spectrometry analyses of p27-KIDp57helix and p27-KID∆C. 
 
p27-KIDp57helix   Expected mass:   10287.4 
                         Observed mass:  10287.6   
p27-KID∆C   Expected mass:  10179.3 
                   Observed mass:  10179.9   
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Figure 2.12 Mass spectrometry analyses of purified p27-KID+H, p27-KID-H, 
and p27-KIDloop. 
p27-KID+H  Expected mass:  10344.7 
                  Observed mass:  10345.9  
p27-KID-H   Expected mass:  10399.3 
                  Observed mass:  10396.0  
p27-KIDloop   Expected mass:  9497.4 
                     Observed mass:  9497.6   
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Figure 2.13 SDS-PAGE analysis of purified p27-KID mutants.  Note that the 
lanes in the upper panel were digitally captured from multiple, individual SDS-
PAGE gels.  However, each of these gels was electrophoresed for a similar 
period of time and, thus, this composite image accurately represents the relative 
mobility of the molecular weight markers and the p27-KID proteins. 
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Figure 2.14 Mass spectrometry analysis of the D2 peptide. 
 
 
 
 
 
 
D2 peptide 
 
Expected mass      6219.0 
Observed mass     6219.5 
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ternary complexes with Cdk2/cyclin A for thermal denaturation experiments or 
kinase assays, p27-KIDwt and its variants were treated with 100 mM dithiothreitol 
(DTT) at room temperature for 30 minutes followed by gel filtration 
chromatography purification using an Superdex S-75 column equilibrated with 
buffer GF (20 mM HEPES pH 7.5, 300 mM NaCl, 5 mM DTT).  Unless stated 
otherwise, all gel fitration chromatography purifications were performed in 
columns equilibrated with buffer GF.  The D2 peptide was also treated in the 
same manner as the p27-KID mutants before ITC experiments and kinase 
assays. 
 
2.8 Expression and purification of cyclin A and phosphorylated Cdk2 
 A pET28 plasmid encoding human cyclin A (residues 173-432) had 
previously been prepared in the lab.197  Cyclin A was expressed in E.coli at 37 °C 
in LB media grown to early log phase (A600 ≈ 0.4).  The temperature was reduced 
to 20 °C and protein expression was induced with 1 mM IPTG when the cell 
density reached an A600 ≈ 0.8.  The cells were then cultured for 20 hours and 
harvested by centrifugation. The protein was purified by nickel affinity 
chromatography (as described in Section 2.7; 50% Ni-B was used for elution) 
followed by ammonium sulfate ((NH4)2SO4) precipitation.  Maximal precipitation  
of the cyclin A protein during the (NH4)2SO4 precipitation were achieved by 
adding finely ground (NH4)2SO4 (0.56 g of (NH4)2SO4 for every ml of protein 
solution; 85 % saturation) to protein solutions with a total protein concentration 
greater than 3 mg/ml. The precipitated protein was resuspended in TcycA –buffer 
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(20 mM Tris pH 8.0, 1.0 M NaCl, 2.5 mM CaCl2) and cleaved using thrombin 
overnight at 4 °C.  The cleaved cyclin A protein wa s further purified by anion 
exchange chromatography using Q-sepharose resin and stored at -20 °C after a 
second (NH4)2SO4 precipitation step.  Before use in experiments, the stored 
protein was purified by gel filtration chromatography using a superdex S-75 
column. 
 A bicistronic plasmid vector encoding full length human Cdk2 and civ1 (a 
yeast CAK)216 was kindly provided by Dr. Jane Endicott, Oxford University, 
Oxford, UK.  Both the Cdk2 and civ1 proteins are fused to GST tags at their  
N-termini.  civ 1 is a Cdk-activating kinase that phosphorylates Cdk2 on 
threonine-160.217  This vector was used to express P-Cdk2, full length human 
Cdk2 phosphorylated at threonine-160.  P-Cdk2 expression was performed using 
the same procedure as discussed earlier for truncated human cyclin A.  The 
protein was first purified by glutathione-affinity chromatography followed by 
dialysis into Pre-Scission cleavage buffer (50 mM Tris pH 7.0, 150 mM NaCl, 1 
mM EDTA, 1 mM DTT).  The purified protein was cleaved overnight using  
Pre-Scission protease (GE Healthcare, Piscataway, NJ) enzyme at 4°C.  Only 
the GST-P-Cdk2 fusion protein contains the Pre-Scission cleavage site and ipso 
facto only the P-Cdk2 protein is cleaved from the GST fusion protein.  Cleaved P-
Cdk2 was purified using a second glutathione-affinity chromatography step.  
GST-civ1, the cleaved GST tag from GST-P-Cdk2 fusion protein, uncleaved 
GST-P-Cdk2, and pre-scission enzyme (Pre-Scission is GST tagged) were 
retained on the column while cleaved P-Cdk2 flowed through the column.   
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P-Cdk2 was then concentrated by ammonium sulfate precipitation (in the same 
way as cyclin A above) and stored at -20 °C.  Befor e use in experiments, the 
stored P-Cdk2 protein was purified by gel filtration chromatography superdex  
S-75 column.  
 To prepare the P-Cdk2/cyclin A binary complex, the ammonium sulfate 
precipitated P-Cdk2 and cyclin A stored at -20 ˚C were first separately dissolved 
in buffer GF and the concentration of each protein was determined.  The two 
proteins were then mixed in a 1:1 mole ratio (purified cyclin A to purified P-Cdk2) 
and incubated at 4 ºC for 30 minutes. The binary complex was then purified by 
gel filtration chromatography using a Superdex 75 (S-75) column.  The  
p27-KID/P-Cdk2/cyclin A ternary complexes used in the thermal denaturation 
experiments were made by mixing p27-KIDwt or mutants in a 1.1:1.0 mole ratio 
with the P-Cdk2/cyclin A complex, incubating the mixture for 30 minutes at 4 ˚C 
and purifying the complex using gel filtration chromatography using a Superdex 
200 (S-200) column equilibrated in the thermal denaturation buffer (1 mM 
phosphate pH 7.0, 25 mM NaCl, 1 mM DTT). 
 
2.9 Preparation of retrovirus 
 Retroviruses integrate their genetic material into the genomes of their hosts 
and use the transcription and translation machinery of the host to express viral 
proteins.218  The viral genetic material is replicated by the host cell and new 
viruses are packaged.  The packaged viruses exit the cell and invade the 
neighboring cells.  The viral genome has four DNA modules that are 
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indispensable in invasion and replication: (i) a packaging signal (Ψ) the enables 
packaging of the viral genome into viral particles; (ii) the env gene that encodes 
the viral coat proteins used in the attachment of a virus to a host; (iii) the pol 
gene that encodes the viral polymerase; and (iv) the gag gene that encodes 
proteins that form the viral core structure.219,220  Viral particles are only packaged 
when the Ψ packaging signal is in cis with the the gag, pol and env genes.221  
Retroviral expression systems were designed to take advantage of the 
modularity of the viral genome.222-224  First, a gene of interest (in this case flp27wt 
or its variants) in cis with the retroviral packaging signal is ligated into shuttle 
vector.  The gag, pol, and env genes were ligated into one plasmid or two 
separate plasmids called helper plasmid(s).  The helper plasmid(s) and the 
shuttle vector are then transfected into a packaging cell line.225  The packaging 
cell lines have very high transfection efficiencies and are engineered to optimally 
and stably express the viral gag, pol, and env genes thereby ensuring production 
of high viral titres.  Further, the packaging cell lines are genetically modified to 
prevent production of replication-competent viruses.226,227  In the packaging cell 
line, the gag, pol and env genes cloned into the helper plasmid(s) facilitate the 
packaging of the gene of interest into viral particles in trans.  Only the gene of 
interest is packaged since it is in cis with the Ψ.  The viral particles with the gene 
of interest are then used to transduce a non-packaging cell line.  Since there are 
no gag, pol or env genes in the non-packaging cell line, the viruses with the gene 
of interest can only transduce the cells but cannot replicate.  For my studies, the 
MSCV-I-GFP shuttle vectors in which the flp27wt or its variants were cloned 
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(described in Section 2.5) and a helper plasmid were used to prepare 
retroviruses. 
 First, the the viruses were packaged in the 293T packaging cell line.100 
mm x 10 mm plates of 293T cells were cultured at 37°C in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2% of 
200 mM glutamine (vol:vol), and 1% of 10,000 µg/µl penicillin/streptomycin 
(vol:vol).  Hereafter, the DMEM supplements are referred to as additives.  3 x 106 
cells were cultured on each plate.  After 24 hours, the cell culture media (with 
additives) was substituted with additive free media (DMEM only) and incubated 
for 3 hours.  During this time, transfection cocktails were prepared.   
 The cocktails contained a single helper DNA (containing the viral gag-pol-
env genes), shuttle vector DNA plasmid, fugene 6 transfection reagent (Roche, 
Basel, Switzerland) and additive free DMEM media.  The helper DNA was 
obtained from Dr. Martine Roussel (St. Jude Children’s Research Hospital, 
Memphis, TN).  In every cocktail, the ratio of the volume of the fugene reagent to 
the amount of the shuttle vector (by mass) was varied to identify the ratio that 
yielded the highest viral titre.  The volume of the fugene reagent was kept 
constant at 15 µl and the amount of the shuttle vector added was varied to give 
different fugene to shuttle vector ratios.  Cocktails with volume of fugene to mass 
of shuttle plasmid DNA ratios of 1:20, 1:15, 1:12, and 1:10 were prepared for 
each construct (each construct had 4 cocktails).  A constant 6 µg of helper DNA 
was added to each coctktail.  Serum free media was added to bring the total 
volume of each cocktail to 700 µl.  Before addition of fugene to the cocktails, it 
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was first warmed to room temperature according to manufacturer’s instructions.  
For each cocktail, the reagents were added in the following order:  (i) serum free 
media, (ii) helper DNA, (iii) vector DNA, and (iv) fugene.  The cocktails were then 
mixed.  After 3 hours, the transfection cocktails were added to the incubated 
cells.   
 After 20 hours the additive free media was replaced with 10 ml of fresh 
media supplemented with additives.  In the following steps, all the media was 
supplemented with additives unless stated otherwise.  After 6 hours, the media 
was aspirated from the plates and 5 ml of media was added to each plate.  After 
18 hours, 5 ml of the media containing virus was harvested and 5 ml of fresh 
media was added to each plate.  8 hours later, 5 ml of media containing virus 
was again harvested and a fresh 7 ml of fresh media added to each plate.   
Virus-containing media (7 ml) was harvested a final time after an additional 20 
hours.  The harvested virus was filtered using a 0.22 µm steriflip filter (Millipore, 
Millerica, MA) and stored at 4 °C. 
 
2.10 Viral transduction and cell cycle arrest analysis 
 3 x 105 NIH 3T3 cells were cultured on 100 x 10 mm plates in DMEM media 
with additives (additives specified in section 2.9 above).  After 20 hours, the 
media was aspirated from each plate.  5 ml of cold virus (virus kept in ice) 
supplemented with 30 µl of 1 mg/ml of polybrene (6 µl of polybrene for every ml 
of virus) was added to each plate and incubated at 37 °C.  After 3 hours, 10 ml of 
DMEM media with additives was added to each plate.  After 48 hours, the cells 
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were washed, re-suspended in additive-free DMEM media, and the viral titre 
determined using GFP fluorescence analysis (Flow Cytometry Facility, St. Jude 
Children’s Research Hospital, Memphis, TN).  Before GFP analysis, viable cells 
were separated from non-viable cells by propidium iodide (PI) staining.  For PI 
staining, the cells were first mixed until a single suspension of cells was realized.  
The cells were then counted and washed once with phosphate buffered saline 
(PBS).  The supernatant was decanted and the cells were resuspended in PI 
solution (0.05 mg/ml propidium iodide) at 1 x 106 cells/ml.  This was followed by 
treatment with RNAse for 30 minutes at room temperature.  Prior to and after the 
RNAse step, the cells were kept in ice.  The cells were then filtered using a 40 
µm-diameter mesh (Small Parts Inc., Miami Lakes, FL) to eliminate large 
multicellular clumps that might clog the flow cytometer.  The filtered cells were 
analyzed by flow cytometry. 
 For cell cycle analysis, viral solutions with high viral titres, as determined by 
GFP analysis, were used to transduce NIH 3T3 cells as described above.  The 
cells were washed, and analyzed for viral transduction using GFP analysis.  The 
top 10% GFP positive cells were stained by PI and analyzed for DNA content. 
Each cell cycle arrest analysis was performed in triplicate for each construct.  
 
2.11 Protein concentration determination 
The concentrations of the prepared proteins were determined by UV 
absorbance at 280 nm in a denaturing buffer containing 20 mM phosphate pH 
6.5, and 6.0 M guanidinium hydrochloride.228,229  The molar extinction coefficients 
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were determined using the ProteinParameters tool (ExPASy server; 
http://us.expasy.org/tools/protparam.html) as: 15 220 M-1 cm-1 for p27-KIDwt,  
p27-KIDp57helix, p27-KID ∆C, p27-KID+H, p27-KID-H and p27-KIDloop ; 15 470 
M-1 cm-1 for D2 and p27-KID p21helix;  and 35 560 M-1 cm-1, 31 860 M-1 cm-1 and  
33 710 M-1 cm-1  for P-Cdk2, cyclin A, and the P-Cdk2/cyclin A complex 
respectively.  The extinction co-efficient for the p27-KIDwt, p27-KID p57helix,  
p27-KID ∆C, p27-KID+H, p27-KID-H and p27-KIDloop ternary complexes was 
determined as 24 465 M-1 cm-1.  An extinction coefficient value of 24 590 M-1 cm-1 
was used for the p27-KIDp21helix ternary complex. The p27, p21, and p57 linker 
domain peptides all had an extinction coefficient of 5690 M-1 cm-1. 
 
2.12 Secondary structure analysis by circular dichroism (CD) 
spectropolarimetry  
 The secondary structures of the p27-KID and its mutants were analyzed 
using an AVIV model 62A DS CD spectropolarimeter.  All the samples were 
analyzed in a buffer containing 10 mM phosphate pH 7.0 and 5 mM DTT.  The 
experiments were performed at 25 °C.  At least 3 CD  traces were averaged for 
each sample with a 5 second signal averaging time for each data point.  To 
determine the helical contents of the p27-KID mutants relative to the wild-type, 
the CD spectra of all the proteins to be compared were obtained under exactly 
the same conditions.  For these experiments, the protein concentration in each 
sample was 20 µm.  The CD spectra were collected in a 1 mm path length CD 
cuvette to maximize the signal to noise ratio. 
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2.13 Thermal denaturation experiments 
 The thermal denaturation of the ternary complexes formed by the p27-KIDwt 
and its mutants on binding the P-Cdk2/cyclin A complex was monitored in the 
temperature range of 15 ºC to 95 ºC using an AVIV model 62A DS circular 
dichroism spectropolarimeter equipped with a Pelltier thermoelectric temperature 
control device.  The samples, each containing 400 nM of protein in 1 mM sodium 
phosphate buffer, pH 7.0, 25 mM NaCl and 1 mM DTT, were analyzed in a 1 cm  
path length quartz cuvette.  For these studies, denaturation was monitored by 
measuring ellipticity at 222 nm at 1 ºC intervals at a heating rate of 5 ºC min-1 
with constant stirring.  Three experiments were performed with ternary 
complexes comprised of P-Cdk2/cyclin A and p27-KIDwt, p27-KID+H, p27-KID-H, 
p27-KIDloop, or p27-KIDp57helix, and two experiments were performed with ternary 
complexes containing p27-KIDp21helix or p27-KID∆C.  The denaturation curves 
were analyzed as previously described by Bowman, et al.,216 as follows: 
The fraction of unfolded protein (fD) at any given temperature was calculated from 
the corresponding experimental ellipticity value θ
 
using Equation 2.1: 
 
 fD = [θ – (θN + mNT)] / [(θD + mDT) – (θN + mNT)] (Eq. 2.1) 
 
where T is the temperature, θN and θD are the ellipticity values corresponding to 
the native (N) and denatured (D) states extrapolated to T = 0, and mN and mD are 
the slopes of the baselines preceding and following the transition region obtained 
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by linear regression analysis.  The free energy of unfolding, ∆GD-N, was calculated 
using Equation 2.2: 
 
 ∆GD-N = -RT ln K = -RT ln { fD / (1- fD)} (Eq. 2.2) 
 
to calculate Tm, ∆GD-N values over the transition region of the denaturation curve 
were plotted against temperature and fit to a straight line by linear regression.  Tm 
corresponds to the intercept of the x-axis where ∆GD-N is equal to zero (this is the 
temperature at which fD = fN).  The melting temperature for each sample was 
determined at least two times.  The experimental error in the determination of the 
melting temperature was calculated by determining the standard deviation from 
the mean Tm for each sample. 
 
2.14 Determination of thermodynamic parameters by ITC 
 The thermodynamic parameters associated with p27-KIDwt and the mutant 
proteins binding to P-Cdk2/cyclin A were determined using isothermal titration 
calorimetry (ITC).  The experiments were performed using a VP-ITC calorimeter 
(Microcal, Northampton, MA).  A major advantage of ITC is that the enthalpy of 
association (∆H), binding stoichiometry (n), and binding affinity (Ka; within certain 
limits) of the two interacting components can be determined in a single 
experiment.  It is important to note that ITC cannot accurately determine the 
binding affinity associated with very tight interactions (low nM binding affinity) 
because such systems have a very high c value – c is defined by Wiseman, et 
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al.230  However, accurate estimates can be obtained.  The Gibbs free energy of 
association (∆G) is calculated using the equation ∆G = -RT ln(1/Ka), where R is 
the gas constant (1.987 cal mol-1 K-1) and T is the temperature (degrees Kelvin) 
at which the experiment was performed.  Given that the above limitation applies, 
the values of the Gibbs free energy of association of p27-KIDwt, p27-KID+H,  
p27-KID-H, p27-KIDp57helix, p27-KIDp21helix and p27-KID∆C binding to P-Cdk2/cyclin 
A are taken as estimates of the upper limit of the Kd and those of p27-KIDloop, D1, 
and D2 are considered to be accurate. 
 The experiments were performed at 25 ˚C in buffer containing 20 mM 
HEPES pH 7.5, 300 mM NaCl and 5 mM DTT.  For these experiments, the 
syringe volume was 250 µl and the cell volume was 1.3 ml. In each experiment, 
the P-Cdk2/cyclin A complex was in the cell and p27-KIDwt or its variants were in 
the syringe (titrant).  A standard injection protocol was used for each titrant.  2 µL 
of the titrant was first injected followed by 39 injections, 6 µL each, with 300 
seconds between the injections.  The following were the protein concentrations 
used in the ITC studies: 75 µM p27-KIDwt + 7.4 µM P-Cdk2/cyclin A; 73 µM D1  
+ 5.2 µM P-Cdk2/cyclin A; 72.3 µM D2 + 5.61 µM P-Cdk2/cyclin A; 56 µM  
p27-KID+H + 4.2 µM P-Cdk2/cyclin A; 42 µM p27-KID-H + 4.4 µM P-Cdk2/cyclin A; 
and 36.4 µM p27-KIDloop + 3.1 µM P-Cdk2/cyclin A; 56.87 µM p27-KIDp21helix  
+ 6.22 µM P-Cdk2/cyclin A; 53.57 µM p27-KIDp57 helix + 4.6 µM P-Cdk2/cyclin A; 
and 35 µM p27-KID∆C + 2.88 µM P-Cdk2/cyclin A.  The samples were degassed 
before the experiments were performed and the instrument was regularly 
calibrated as specified by the manufacturer.  The binding data were fit to a 1:1 
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binding model using the Origin software (Origin Lab Corporation, Northampton, 
MA).  This analysis yielded values of the enthalpy of binding (∆H), the equilibrium 
association constant (Ka), and the Gibbs free energy of binding (∆G).  The 
product of entropy and temperature (-T∆S) was calculated using Equation 2.3: 
 
 -T∆S = ∆G - ∆H (Eq. 2.3) 
 
2.15 Kinase inhibition assays 
A solution of 80 pM P-Cdk2/cyclin A binary complex containing 2.5 µM 
histone H1 (Upstate, Charlottsville, VA) and varying amounts of p27-KIDwt or its 
mutants was incubated at 4 ºC for 1 hour.  6 µCi of γ32P-ATP (PerkinElmer, Inc., 
Wellesley, MA) was added to each reaction and incubated at 30 ºC for 35 
minutes.  The concentration of the γ32P-ATP was 1 mCi/ml (1 part 10 mCi/ml of 
γ32P-ATP to 9 parts 111 µM cold ATP) and the total reaction volume was 15 µl.  
All the samples were in a kinase assay buffer containing 20 mM HEPES pH, 7.3, 
25 mM sodium b-glycerolphosphate, 15 mM MgCl2, 16 mM EGTA, 0.5 mM 
Na3VO4 and 10 mM DTT.  The kinase reactions were quenched by adding  
SDS-PAGE gel loading buffer.  The samples were then analyzed by SDS-PAGE 
and the bands quantified using a phosphoimager (Molecular Dynamics, 
Sunnyvale, CA).  The inhibition data was fit to a dose-response model using 
Graphpad Prism software (Graphpad Software, Inc., San Diego, CA).  Each 
curve was fit from a triplicate set of experiments.  The error was reported as the 
95% confidence interval of the IC50 from a curve fit of a triplicate data set.  
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Chapter 3: The linker domains of proteins in the Cip/Kip family play similar 
structural roles 
  
The structure of the linker domain of p21, p27, and p57 is conserved, and 
this domain serves to couple the D1 and D2 domains of Cip/Kip proteins.  In the 
first study of this chapter, I have investigated the effects of deleting the linker 
domain on the function of p27 as a cyclin-dependent kinase inhibitor.  The 
thermodynamics of association of peptides corresponding to the D1 and D2 
domains of the KID with the P-Cdk2/cyclin A complex relative to the p27-KIDwt 
were analyzed.  The functional consequences of deleting the linker domain were 
determined by studying inhibition of the P-Cdk2/cyclin A catalytic activity by D2 
peptide.  
Although the nascent helical structure of the linker domain is conserved 
amongst members of the Cip/Kip family, its sequence is not.  However, the 
sequence of the linker domain for each Cip/Kip protein is highly conserved in 
different species suggesting that the sequences of these proteins may be 
important for their function.  In the second study in this chapter, I investigated 
whether the linker domains of the Cip/Kip proteins, despite having different 
sequences, play similar structural roles.  Chimeric Cip/Kip proteins were used for 
these studies.  The chimeric proteins were prepared by replacing the linker 
domain of the p27-KID with either the p21 linker domain (p27-KIDp21helix) or the 
p57 linker domain (p27-KIDp57helix). The interaction of these chimeric proteins with 
the P-Cdk2/cyclin A kinase complex was then probed.  This chimeric mutant 
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model is suitable for these studies for two reasons.  First, the individual linker 
domains of p21, p27 and p57 have an inherent propensity to form α-helices 
indicating that this domain can fold independent of the rest of the KID 
polypeptide.  Secondly, the residues neighboring the linker domains in the native 
proteins are well conserved.  This minimizes the variation in stabilization of the 
linker helix by the neighboring residues.  By replacing only the linker domain and 
keeping D1 and D2 constant, the consequences of linker domain swapping on 
the interaction with the P-Cdk2/cyclin A complex can be studied.   
Only 3 out of the 22 residues in the linker domains of p21, p27, and p57 
are conserved.  The role of these conserved residues in the interaction of the 
Cip/Kip proteins with Cdk complexes is unknown.  In the final study of this 
chapter, I have investigated the role of these conserved residues by preparing a 
p27-KID variant in which the three conserved residues in the linker domain are 
mutated to glycines (Glu39Gly/Leu41Gly/Arg43Gly, the p27-KID∆C mutant) and 
probing its interaction with the P-Cdk2/cyclin A complex.   
In all the studies, CD was used to study the secondary structures of the 
mutants. The relative stabilities of the ternary complexes formed by the variants 
on binding to P-Cdk2/cyclin A were determined by monitoring the ellipticity of 
each complex at 222 nm as a function of temperature.  ITC was used to 
determine the thermodynamics of association of the mutants with the  
P-Cdk2/cyclin A complex. Kinase inhibition assays were performed to provide 
insights into the consequences of the mutations on the kinase inhibition activity of 
the Cip/Kip proteins. 
 72 
3.1 The nascent helical character of the linker domain is preserved in the 
chimeric mutants and the p27-KID∆C mutant 
 The secondary structures of the p21, p27, and p57 linker domain peptides, 
and the p27-KIDwt, p27-KIDp21helix, p27-KIDp57helix, p27-KID∆C, were determined by 
CD (Figure 3.1 and Figure 3.2).  The linker domain peptides are mainly 
unstructured (ellipticity at about 200 nm), with some helical secondary structure 
(ellipticity at 222 nm).  These results are consistent with secondary structure 
prediction for the linker domains of p27, p21, and p57.197   The p21 helix peptide 
shows a significantly higher content of random coil than either p27 or p57 linker 
helix peptides.  This is not surprising since its sequence has a glycine (Gly40) 
which would effectively decrease its helical content and increase its overall 
random coil composition relative to the p27 and p57 helix peptides. The presence 
of nascent α-helical secondary structure in all the linker domain peptides 
indicates that their sequences have an intrinsic tendency to form α-helices and 
can fold independent of the rest of the KID sequence.  The stabilization of the 
linker domains in the context of the KID should be very similar since the residues 
neighboring the linker domains in the p21, p57, and p27 proteins are well 
conserved. 
The chimeric mutants have secondary structures very similar to that of the 
p27-KIDwt.  They are largely unstructured with nascent helical characteristics.  
The mean residue molar ellipticity values of the chimeric mutants at 222 nm 
([Θ222]) are comparable to that of the p27-KIDwt indicating that they have 
comparable helical contents.  The results of the secondary structural analysis of  
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Figure 3.1 CD spectra of the p21, p27, and p57 linker domain peptides.  
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Figure 3.2 CD spectra of p27-KIDwt, p27-KIDp21helix, p27-KIDp57helix, and p27-
KID∆C. 
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 the chimeric mutants suggest that the linker domains of p21 and p57, despite 
having different sequences and being bordered by D1 and D2 domains of p27, 
adopt structures similar to their previously reported secondary structures in the 
context of p21-KID and p57-KID, respectively.188,198  Further, this shows that our 
chimeric mutant model does not cause major changes in the secondary structure 
and hence is suitable for probing the structure conservation/sequence 
divergence relationship of the linker domains of p27, p21, and p57.   
The p27-KID∆C mutant also exhibits a largely disordered secondary 
structure with nascent helical characteristics (Figure 3.2).  The [Θ222] of this 
mutant is comparable to that of the wild-type p27-KID indicating that the two  
p27-KID variants have comparable helical contents.  These results suggest that 
the mutation of the conserved residues in the linker domain to glycines does not 
cause a major structural change.  This structural similarity suggests that any 
disparities in the interaction between p27-KID∆C and the P-Cdk2/cyclin A complex 
relative to the p27-KIDwt are not a consequence of perturbation of the structure of 
the linker domain. 
 
3.2 Binding thermodynamics determined by ITC 
The thermodynamics of the association of the p27-KIDwt and its variants 
with the P-Cdk2/cyclin A complex were characterized by ITC.  First, the 
thermodynamic parameters of the binding of either the D1 or the D2 peptide to 
the binary complex were compared to those of p27-KIDwt.  The binding of either 
D1 or D2 to P-Cdk2/cyclin A is much weaker than that of p27-KIDwt.  The 
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dissociation constants for the p27-KIDwt, D1, and D2 were determined to be 3.34 
± 1.64 nM, 42.20 ± 5.16 nM, and 82.96 ± 17.89 nM, respectively (Table 3.1).  
These results show that the coupling of D1 and D2 via the linker domain greatly 
increases the affinity of p27 for the kinase complex.  The ∆G’s of association of 
p27-KIDwt, D1, and D2 with the P-Cdk2/cyclin A complex are -10.06 ± 0.07 kcal 
mol-1 and -9.66 ± 0.12 kcal mol-1, and -11.61 ± 0.30 kcal mol-1, respectively.  The 
sum of the ∆H values for the interactions of D1 and D2 with P-Cdk2/cyclin A is  
-47.69 kcal mol-1 relative to the -43.77 kcal mol-1 of heat released when  
p27-KIDwt binds to the same complex.  This suggests that the P-Cdk2/cyclin A 
bound conformation(s) of either the D1 or D2, or both peptides, is slightly 
different from its/their conformation(s) in the context of p27-KID. 
The chimeric mutants bound to the P-Cdk2/cyclin A complex with affinities 
very similar to that of p27-KIDwt (Table 3.1).  Figure 3.3 shows the binding 
isotherms for the interactions between p27-KIDwt or its variants with the  
P-Cdk2/cyclin A complex.  The dissociation constants for p27-KIDp21helix and  
p27-KIDp57helix were 2.83 ± 1.37 nM, and 0.49 ± 0.14 nM respectively.  Similar to 
that for p27-KIDwt, the binding of each chimeric mutant to the P-Cdk2/cyclin A 
complex was associated with a large entropic penalty.  -T∆S values of +32.16  
± 1.22 kcal mol-1, +16.24 ± 1.29 kcal mol-1, and +18.44 ± 0.35 kcal mol-1 were 
obtained for the p27-KIDwt, p27-KIDp21helix, and p27-KIDp57helix respectively.  
However, the disparities -T∆S values suggest that the chimeric mutants do not 
fold to the same extent as the p27-KIDwt.  Although there are differences in the 
folding of the chimeric mutants relative the p27-KIDwt on binding the  
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Table 3.1.  Thermodynamic parameters determined by ITC at 25 ˚C. 
 
 
Interaction Kd (nM) 
∆Ga 
(kcal mol-1) 
∆H 
(kcal mol-1) 
-T∆Sb 
(kcal mol-1) 
D1 + P-Cdk2/cyclin A 42.20 ± 5.16 - 10.06 ± 0.07 - 16.14 ± 0.20 + 6.08 ± 0.27 
D2 + P-Cdk2/cyclin A 82.96 ± 17.89 -  9.66 ± 0.12 - 31.55 ± 1.66 + 21.89 ± 1.53 
p27-KIDwt + P-Cdk2/cyclin A 3.34 ± 1.64 - 11.61 ± 0.30 c - 43.77 ± 1.38 + 32.16 ± 1.22 
p27-KIDp21helix + P-Cdk2/cyclin A 2.83 ± 1.37 - 11.70 ± 0.27 c - 27.94 ± 1.26 + 16.24 ± 1.29 
p27-KIDp57helix + P-Cdk2/cyclin A 0.49 ± 0.14 - 12.71 ± 0.17 c - 31.15 ± 0.51 + 18.44 ± 0.35 
p27-KID∆C + P-Cdk2/cyclin A 1.97 ± 0.65 - 11.89 ± 0.21 c -39.65 ± 0.13 + 27.76 ± 0.17 
 
 
In all the experiments above, the stoichiometry of binding was determined as one 
(1), with experimental error within 10%.  The errors reported above are the 
standard deviations from the mean of three independent experiments. 
a
 Calculated with the equation ∆G = -RT ln(1/Kd ). 
b
 Calculated with the equation ∆G = ∆H -T∆S. 
c
 The c values for these p27-KID variants are very high and the ∆G values 
reported here are taken as estimates of the upper limits of Kd.  Ideal c values for 
accurate determination of Kd have a range of 1 to 500.  The c values for the 
binding of p27-KIDwt, p27-KIDp21helix, p27-KIDp57helix, and the p27-KID∆C to  
P-Cdk2/cyclin A complex are 2212, 2195, 9387, and 1461, respectively. 
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Figure 3.3 ITC binding isotherms for the p27-KID variants. 
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P-Cdk2/cyclin A complex, data from the binding of D1 and D2 with the same 
complex suggest that the D1 and D2 domains of these mutants bind to the 
kinase complex.  The chimeric mutants have much higher binding affinities for 
the P-Cdk2/cyclin A complex than either D1 or D2 (Table 3.1).  This stems from 
the linkage by the linker domain.  In addition, the association of the the chimeric 
mutants with P-Cdk2/cyclin A is more favorable than that of D1 or D2.  Further, 
the Gibbs free energy of association for the chimeric mutants with P-Cdk2/cyclin 
A is more favorable than ∆G values previously reported for the interactions of 
p27-KIDwt with either Cdk2 or cyclin A.197  The differences in the folding of the 
p27-KIDwt and the chimeric mutants are further seen in the enthalpy values 
obtained for their interaction with the P-Cdk2/cyclin A complex.  Enthalpy values 
of -43.77 ± 1.38 kcal mol-1, -27.94 ± 1.26 kcal mol-1, and -31.15 ± 0.51 kcal mol-1 
were obtained for the p27-KIDwt, p27-KIDp21helix, and p27-KIDp57helix respectively.  
The differences in ∆H are most likely caused by the interactions of different sets 
of residues in the linker domains of p27-KIDwt, p27-KIDp21helix, and p27-KIDp57helix 
(recall that the sequences linker domains of the Cip/Kip proteins are not 
conserved). The enthalpy values show that the interactions of the chimeric 
mutants with the P-Cdk2/cyclin A complex have fewer favorable contacts with 
respect to the p27-KIDwt.  Nevertheless, the enthalpy generated by each chimeric 
mutant compensates for the entropic cost associated with the folding on binding 
the P-Cdk2/cyclin A complex making the free energies of the interactions 
negative and favorable – entropy-enthalpy compensation.  Entropy-enthalpy 
compensation is a phenomenon in which the enthalpy change in a system during 
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a chemical process (in which the experimental conditions are varied) is partially 
or completely compensated for by a corresponding change in entropy such that 
the net free energy change is very small.  As an example, the decrease in the 
absolute magnitude of ∆H in the interactions of p27-KIDp21helix and p27-KIDp57helix 
with P-Cdk2/cyclin A relative to p27-KIDwt caused by the differences in the 
sequences of the linker domains (variation in experimental conditions) is 
compensated for by a proportionate decrease in the entropic cost of binding; the 
residues that make fewer favorable contacts (release less heat) have more 
degrees of freedom (increase in entropy).  Entropy-enthalpy compensation 
therefore results in a narrow range of variation of ∆G between the native system 
and the system with varied experimental conditions.  The ∆G values of the 
interactions of p27-KIDwt, p27-KIDp21helix, and p27-KIDp57helix with P-Cdk2/cyclin A 
vary within a narrow range indicating that, despite the enthalpic differences, the 
linker domains have very similar ∆G contributions to the interaction of the Cip/Kip 
proteins with the P-Cdk2/cyclin A complex.  The free energies of association for 
the p27-KIDwt, p27-KIDp21helix, and p27-KIDp57helix were -11.61 ± 0.30 kcal mol-1,  
-11.70 ± 0.27 kcal mol-1, and -12.71 ± 0.17 kcal mol-1 respectively. 
The interaction of the p27-KID∆C mutant with the P-Cdk2/cyclin A complex 
relative to the p27-KIDwt shows the thermodynamic contributions of the 
conserved residues within the linker domain.  This mutant binds very tightly to the 
kinase complex with a Kd of 1.97 ± 0.65 kcal mol-1 (Figure 3.3, Table 3.1).  
Similar to the chimeric mutants, it also folds extensively on binding the  
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P-Cdk2/cyclin A complex and has a -T∆S value of +27.76 ± 0.17 kcal mol-1.  This 
extensive folding on binding, as is expected, is accompanied by the release of a 
large amount of heat.  The enthalpy of association of the p27-KID∆C mutant with 
P-Cdk2/cyclin A complex is -39.65 ± 0.13 kcal mol-1.  The enthalpic contribution 
of the conserved residues is about 4.12 kcal mol-1 (about 9.4% of the total heat 
released).  The net free energy obtained for the interaction of the p27-KID∆C with 
the P-Cdk2/cyclin A complex is - 11.89 ± 0.21kcal mol-1.  The ∆G of the 
interaction of the p27-KID∆C mutant to the P-Cdk2/cyclin A complex is therefore 
the same as that for the p27-KIDwt within the error range.  This shows that even 
though there is a slight decrease in enthalpy of interaction of the p27-KID with 
the P-Cdk2/cyclin A complex in the absence of the conserved residues within the 
linker domain, this loss is completely compensated for by a proportionately 
reduced entropic cost – entropy-enthalpy compensation. 
 
3.3 The p27-KIDwt ternary complex is more stable than the corresponding 
complexes of its variants 
Previous studies have shown that the binding of the p27-KID to  
P-Cdk2/cyclin A stabilizes that binary kinase complex and increases its melting 
temperature (Tm).216  While the P-Cdk2/cyclin A complex has a Tm of  
54.7 ± 0.6 ˚C, the p27-KID/ P-Cdk2/cyclin A ternary complex has a Tm of 82.3 ± 
0.5 ˚C, an increase of 27.6 ˚C in the melting temperature.  I investigated the 
consequences of linker domain swapping (chimeric mutants), and the role of the 
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conserved residues within the linker domain on the stabilization of the binary 
complex by determining the Tm’s of their ternary complexes on binding the  
P-Cdk2/cyclin A complex.  The melting temperature (Tm) for each protein 
complex was determined by using standard thermal denaturation curve-fitting 
equations231 to analyze the temperature dependence of [Θ222] using CD.  The 
thermal denaturation curves for the ternary complexes of p27-KIDwt,  
p27-KIDp21helix, p27-KIDp57helix, and p27-KID∆C are shown in Figure 3.4.  It is 
significant to note that the thermal denaturation process for the complexes in this 
study is irreversible due to protein aggregation at temperatures above their Tm 
values.  Our results show that the ternary complex containing p27-KIDwt (Tm = 
82.3 ± 0.5 ˚C) is slightly more stable than those containing p27-KIDp21helix or  
p27-KIDp57helix which have Tm values of 80.7 ± 0.2 ˚C and 80.1 ± 0.1 ˚C (Table 
3.2), respectively.  The p27-KID∆C is the least stable of the three mutants relative 
to the p27-KIDwt and has a Tm of 74.1 ± 0.6 ˚C.  The relative instability of the  
p27-KID∆C is probably caused largely in part by the mutation of Leu41 which in 
the crystal structure of the p27-KIDwt/Cdk2/cyclin A complex104 is buried in the 
p27-KIDwt/cyclin A binding interface.  By mutating this residue to a glycine, I have 
decreased the buried surface area at this position and consequently diminished 
the extent of favorable inter-molecular interactions.  The other conserved 
residues, Glu39 and Arg43, are solvent exposed and most likely do not 
contribute significantly to the interaction of the linker domain with the cyclin A.  
This result indicates that the conserved residues of the linker helix contribute 
significantly to the stability of the ternary complex (by about 8ºC).      
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Figure 3.4 Thermal denaturation curves of the p27-KID mutants.  
 
 
 
 
 
 
p27-KID 
p21 helix
p27-KIDp57 helix
p27-KID 
∆C
p27-KIDwt
0
0.2
0.4
0.6
0.8
1
0 20 40 60 80 100
Temperature ( °C)
Fr
ac
tio
n
 
u
n
fo
ld
ed
Fr
ac
tio
n
 
u
n
fo
ld
ed
 84 
Table 3.2 Melting temperatures of ternary complexes formed by either  
p27-KIDwt or its variants bound to P-Cdk2/cyclin A complex. 
 
 
Complex Tm (˚C) 
p27-KIDwt/P-Cdk2/cyclin Aa 82.3 ± 0.5 
p27-KIDp21helix/P-Cdk2/cyclin Ab 80.7 ± 0.2 
p27-KIDp57helix/P-Cdk2/cyclin Aa 80.1 ± 0.1 
p27-KID∆C/P-Cdk2/cyclin Ab 74.1 ± 0.6 
 
 
a
 The error reported is the standard deviation from the mean of three 
independent experiments. 
b
 The error reported is the standard deviation from the mean of two independent 
experiments. 
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 3.4 Relative inhibition potency determined by in vitro kinase assays 
Kinase inhibiton assays were performed to probe the P-Cdk2/cyclin A 
kinase inhibition potency of the p27-KID mutants with respect to the p27-KIDwt.  
In these studies, the P-Cdk2/cyclin A kinase concentration was 80 pM to avoid 
depletion of the inhibitors which would be the case at much higher kinase 
concentrations.  All the proteins used in these studies were exchanged into the 
kinase assay buffer (buffer KA) by gel filtration chromatography.  This was 
necessary because these assays are very sensitive to differences in solution 
conditions.  It was therefore very important to prepare all the samples under 
exactly the same buffer conditions in order to obtain comparable results for the 
various p27-KID variants. 
Studies of the inhibition potency of D2, Figure 3.5, Table 3.3, shows that it 
is a poor inhibitor (IC50 = 125 nM) and cannot completely inhibit kinase activity.  
even at very high D2 inhibitor concentrations, as high as 17.7 µM, P-Cdk2/cyclin 
A retains about 25% of full kinase activity.  This indicates that the isolated D2 
peptide does not fold into the same inhibitory conformation as does D2 in the 
context of the full KID. 
On the other hand, the chimeric mutants are potent kinase inhibitors with 
IC50 values in the low nM range.  Figure 3.6 shows the gels and kinase inhibition 
curves of the chimeric mutants.  The IC50 values for the p27-KIDwt, p27-
KIDp21helix, and p27-KIDp57helix were 0.22 nM, 1.73 nM, and 3.45 nM respectively 
(Table 3.3).  These results clearly show that the D2 domains of the chimeric 
mutants are folded into conformations with a capacity of inhibiting the kinase 
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Figure 3.5 Inhibition of P-Cdk2/cyclin A kinase activity by the D2 peptide.  
(a) SDS-PAGE gels showing the inhibition of the P-Cdk2/cyclin A kinase by the 
p27-KIDwt and D2.  PO4-H1 is phosphorylated histone H1.  (b) Inhibition curves 
for the p27-KIDwt and D2 peptide. 
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Table 3.3 Inhibition potencies of the p27-KID variants. 
 
 
Variant IC50  (nM) 95% confidence intervals of IC50 (nM)a 
p27-KIDwt 0.22 0.17 – 0.28 
p27-KIDp21helix 1.73 1.09 – 2.73 
p27-KIDp57helix 3.45 2.32 – 5.13 
p27-KID∆C 2.56 1.70 – 3.87 
D2 125b 45.94 – 340.80 
 
 
a
 Error is reported as the 95% confidence interval of the IC50 from a curve fit of a 
triplicate data set. 
b
 This variant only partially inhibits kinase activity.  25% residual kinase activity 
observed at inhibitor concentrations as high as 17.7 µM. 
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Figure 3.6 Inhibition of P-Cdk2/cyclin A kinase activity by the p27-KID 
variants.  (a) SDS-PAGE gels showing the inhibition of the P-Cdk2/cyclin A 
kinase by the p27-KID mutants.  PO4-H1 is phophorylated histone H1  (b) 
Inhibition curves of the p27-KID mutants. 
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complex.  Even though the chimeric mutants are potent kinase inhibitors, their 
potencies are slightly decreased relative to the p27-KIDwt.  The p27-KIDp21helix 
mutant is about 8 fold less potent than the p27-KIDwt, while the p27-KIDp57helix is 
about 16 fold less potent relative to the wild-type p27-KID.    
The p27-KID∆C mutant is also a potent inhibitor of the P-Cdk2/cyclin A 
kinase activity.  This mutant has an IC50 value of 2.56 nM.  Like the chimeric 
mutants, the p27-KID∆C mutant is less potent than the p27-KIDwt (about 12 times 
less potent).  This suggests that the conserved residues contribute marginally to 
the kinase inhibitory function of p27. 
 
3.5 Summary 
 In this chapter, it has been demonstrated that the binding the D1 and D2 
peptides to the P-Cdk2/cyclin A complex is less favorable relative to that of  
p27-KIDwt.  It has also been shown that the D2 peptide cannot completely inhibit 
the P-Cdk2/cyclin A kinase activity. 
In addition, I have shown that the linker domains of the Cip/Kip proteins 
play similar structural roles, the differences in their sequences notwithstanding.  
The free energies of association of chimeric mutants (created by substituting the 
linker domain of p27 with p21 and p57 linker domains) with the P-Cdk2/cyclin A 
complex are very comparable to the free energy of association of wild-type  
p27-KID with the same complex.  The melting temperatures of the ternary 
complexes formed by the chimeric mutants on binding the P-Cdk2/cyclin A 
complex are very similar to that of the ternary of the p27-KIDwt.  The chimeric 
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mutants are potent inhibitors of the kinase activity of P-Cdk2/cyclin A, with IC50 
values in the low nM range.   
 Data from the third study shows that three conserved residues within the 
linker domains of the Cip/Kip proteins do not contribute significantly to the Gibbs 
free energy of association in the binding of p27-KID to the P-Cdk2/cyclin A.  
However, the conserved residues contribute to the thermal stability of the ternary 
complex formed when p27-KID binds the P-Cdk2/cyclin A complex.  Further, 
these residues contribute, albeit marginally, to the inhibition of the P-Cdk2/cyclin 
A kinase activity. 
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Chapter 4: Consequences of perturbation of the structure of the linker 
domain of p27 
 
 The nascent helical structure of the linker domain is conserved amongst 
members of the Cip/Kip family of cyclin-dependent kinase inhibitors; however, its 
role in function is not known.  To investigate the role of the nascent structure of 
the linker domain, mutants with higher or lower helical contents than the wild-type 
p27-KID in the linker domain were prepared and the consequences of the 
structure perturbations on the interaction of p27-KID with P-Cdk2/cyclin A were 
monitored.  First, the solvent exposed residues within the linker domain were 
substituted with residues that either stabilize or destabilize helices.  The 
secondary structures of the mutants were determined by CD.  The consequences 
of the mutations on the thermodynamics of association of p27 and the  
P-Cdk2/cyclin A were analyzed by ITC.  CD thermal denaturation studies were 
used to determine the thermal stability of the ternary complexes formed by p27 
and its variants bound to P-Cdk2/cyclin A.  The effects of the mutations on p27 
function were determined by Cdk2 inhibition assays and cell cycle arrest 
analysis. 
 
4.1 Secondary structure analysis of the more and less helical p27-KID 
mutants 
 The mutants selected for these studies were part of a larger library of 
mutants as listed in Table 2.2.  Figure 4.1 shows the CD spectra of p27-KIDwt, 
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Figure 4.1 CD spectra of the p27-KID linker domain mutants. 
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p27-KID+H, p27-KID-H, and p27-KIDloop and the differences in their helical 
contents.  p27-KIDloop exhibits random coil structure, suggesting strongly that the 
helical contribution at 222 nm observed in the p27-KIDwt is localized in the linker 
domain and not in D1 or D2.  This is consistent with previous studies.197 
 
4.2 The free energy of the interaction of p27-KID with P-Cdk2/cyclin A does 
not decrease when the helical content in the linker domain of p27 is 
increased 
 The thermodynamic binding parameters associated with the interaction of 
the p27-KID linker domain mutants and the P-Cdk2/cyclin A complex were 
determined by ITC.  Figure 4.2 shows the ITC binding isotherms for these 
mutants.  The interactions of the linker helix mutants with the P-Cdk2/cyclin A 
complex, involve dramatic folding-on-binding and are accompanied by large 
entropic costs, but not to the same extent as the p27-KIDwt.  The observed -T∆S 
values for the p27-KIDwt, p27-KID+H, p27-KID-H, and p27-KIDloop are +32.2 ± 1.2 
Kcal mol-1, +22.3 ± 2.5 Kcal mol-1, +19.0 ± 1.0 Kcal mol-1, and +20.0 ± 1.4 Kcal 
mol-1 respectively (Table 4.1).  This suggests that p27-KID+H, p27-KID-H, and 
p27-KIDloop do not fold to the same extent upon binding to P-Cdk2/cyclin A as 
p27-KIDwt.  The folding of the mutants on binding the P-Cdk2/cyclin A complex 
results in a large number of favorable contacts.  All the mutants release a large 
amount of heat when they bind the P-Cdk2/cyclin A complex.  Nevertheless, the 
enthalpies of interaction for the mutants are smaller in magnitude relative to that 
for p27-KIDwt.  The enthalpies of interaction for the p27-KIDwt, p27-KID+H , 
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Figure 4.2 ITC binding isotherms for the interaction of the p27-KID mutants 
with the P-Cdk2/cyclin A complex.  The transition regions for p27-KIDwt and 
p27-KIDloop are expanded. 
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Table 4.1 Thermodynamic binding parameters of the p27-KID mutants. 
 
 
Interaction Kd
 
(nM) 
∆Ga 
(kcal mol-1) 
∆H 
(kcal mol-1) 
-T∆Sb 
(kcal mol-1) 
p27-KIDwt + P-Cdk2/cyclin A 3.34 ± 1.64 - 11.61 ± 0.30c - 43.77 ± 1.38 + 32.16 ± 1.22 
p27-KID+H + P-Cdk2/cyclin A 23.41 ± 6.09 - 10.42 ± 0.15 - 32.72 ± 2.57 + 22.3 ± 2.46 
p27-KID-H + P-Cdk2/cyclin A 3.66 ± 0.91 - 11.52 ± 0.14c - 30.48 ± 0.82 + 18.96 ± 0.95 
p27-KIDloop + P-Cdk2/cyclin A 138.3 ± 43.05 - 9.37 ± 0.18 -29.12 ± 1.19 + 19.7 ± 1.36 
 
 
In all the experiments above, the stoichiometry of binding was determined as one 
(1), with experimental error within 10%.  The errors reported above are the 
standard deviations from the mean of three independent experiments. 
a
 Calculated with the equation ∆G = -RT ln(1/Kd ). 
b
 Calculated with the equation ∆G = ∆H -T∆S.  
c
 The c values for these p27-KID variants are very high and the ∆G values 
reported here are taken as estimates of the upper limits of Kd.  Ideal c values for 
accurate determination of Kd, have a range of 1 to 500.  The c values for the 
binding of p27-KIDwt and p27-KID-H to P-Cdk2/cyclin A complex are 2212 and 
1698, respectively. 
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p27-KID-H, and p27-KIDloop are -43.8 ± 1.4 kcal mol-1, -32.7 ± 2.6 kcal mol-1, -30.5 
± 0.8 kcal mol-1, and -29.1 ± 1.2 kcal mol-1 in the order given.  These enthalpies 
of interaction, for the wild-type and mutants, overcome the respective 
unfavorable interaction entropies resulting in overall favorable Gibbs free 
energies of interaction.  ∆G values of -11.6 ± 0.3 kcal mol-1, -10.4 ± 0.2 kcal  
mol-1, -11.5 ± 0.1 kcal mol-1, and -9.4 ± 0.2 kcal mol-1 were obtained for the  
p27-KIDwt, p27-KID+H, p27-KID-H, and p27-KIDloop, respectively.  The ∆∆G value 
for the p27-KID+H with respect to the p27-KIDwt is +1.2 kcal mol-1 demonstrating 
that increasing the helical content of the linker domain does not make the 
interaction of p27-KIDwt with P-Cdk2/cyclin A more favorable; in fact, it actually 
makes it slightly less favorable.   
 
4.3 The ternary complexes formed by the linker helix mutants on binding  
P-Cdk2/cyclin A are thermodynamically less stable relative to that of  
p27-KIDwt 
 The P-Cdk2/cyclin A complex has a modest thermal stability with a melting 
temperature (Tm) of 54.7 ± 0.6 ˚C.216  When p27-KIDwt binds to the P-Cdk2/cyclin 
A complex, the thermal stability of the ternary complex is dramatically increased 
to 82.3 ± 0.5 ˚C.  Figure 4.3 shows the thermal denaturation curves of the ternary 
complexes formed by the interaction of the p27-KID linker helix mutants and the 
P-Cdk2/cyclin A complex.  The Tm for values for complexes containing  
p27-KID+H, p27-KID-H, and p27-KIDloop were 80.3 ± 0.2 ˚C, 78.5 ± 0.6 ˚C, and 
73.0 ± 0.3 ˚C respectively (Table 4.2).  The results indicate that perturbation of  
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Figure 4.3 Thermal denaturation curves for the p27-KID variants. 
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Table 4.2 Melting temperatures of the ternary complexes formed by the 
p27-KID mutants on binding the P-Cdk2/cyclin A complex. 
 
 
Complex Tm (˚C) 
p27-KIDwt/P-Cdk2/cyclin A 82.3 ± 0.5 
p27-KID+H/P-Cdk2/cyclin A 80.3 ± 0.2 
p27-KID-H/P-Cdk2/cyclin A 78.5 ± 0.6 
p27-KIDloop/P-Cdk2/cyclin A 73.0 ± 0.3 
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the helical content of the linker domain has a net effect of decreasing the thermal 
stabililty of the ternary complexes.  Reducing the helical content (p27-KID-H) or 
completely eliminating the nascent helical structure (p27-KIDloop) has a greater 
impact on the thermal stability than increasing the helical content (p27-KID+H).  
The decrease in the melting temperature of the ternary complex containing the 
p27-KID+H mutant relative to that of p27-KIDwt indicates that restricting the 
dynamics of the linker domain by stabilizating its helical structure has a 
destabilizing effect on the p27-KIDwt ternary complex.  On the other hand, the 
Tm’s obtained for the p27-KID-H and p27-KIDloop mutants suggest that excessive 
flexibility of the linker domain is also destabilizing.    
 
4.4 The linker helix mutants are less potent inhibitors of P-Cdk2/cyclin A 
kinase activity relative to p27-KIDwt 
In the last chapter, it was shown that p27-KID is a potent inhibitor of the 
kinase activity of the P-Cdk2/cyclin A complex and that a Cdk binding domain 
peptide (D2) cannot completely inhibit kinase activity.  The D2 peptide partially 
inhibits P-Cdk2/cyclin A kinase activity with an IC50 of about 125 nM.  However, 
the D2 peptide fails to completely inhibit P-Cdk2/cyclin A with 25% residual 
kinase activity observed even at inhibitor peptide concentrations as high as 17 
µM.  These data suggest that the Cdk binding domain requires the other domains 
of the KID (the cyclin binding domain and the linker domain) for effective 
inhibition.  The structure of the p27-KID/Cdk2/cyclin A complex shows that the 
the LH domain of p27 is an α-helix in this ternary complex.104  However, the role 
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of the helical propensity of the LH domain of unbound p27 in binding and 
inhibition is not known.  I performed kinase inhibition assays to uncover the 
contribution of the structure of the linker domain to Cdk inhibition. 
All of the linker helix mutants inhibit kinase activity in the low nanomolar  
range.  Nevertheless, none of the mutants is more potent than the wild-type KID.  
Figure 4.4 shows the raw inhibition data and normalized inhibition curves for the 
p27-KID mutants.  The values for the p27-KIDwt, p27-KID+H, p27-KID-H, and  
p27-KIDloop were 293.8 pM, 5.1 nM, 353.0 pM, and 16.0 nM (Table 4.3), 
respectively.  The results obtained for the p27-KIDloop mutant are very interesting 
because they show that a KID molecule formed by coupling the cyclin and Cdk 
binding domains with an unstructured flexible linker can inhibit the P-Cdk2/cyclin 
A cyclin complex with an IC50 as low as 16 nM.  Increasing the helical content of 
the linker domain decreases inhibition potency relative to the p27-KIDwt.  The 
p27-KID+H variant is about 17 times less potent than the wild-type KID in 
inhibiting P-Cdk2/cyclin A kinase activity.  However, reducing the helical content 
(p27-KID-H) does not diminish the inhibition potency of the KID to the same 
extent.  The p27-KID-H is almost as potent as the wild-type KID.  Since the linker 
domain does not have extensive interactions with either cyclin A or P-Cdk2, its 
effects on phosphorylation are most likely a consequence of the role it plays in 
the folding of the Cdk binding domain.  
 It should be noted that the disparity between the IC50 value, (16 nM), and 
Kd value, (138 nM), for the p27-KIDloop mutant is likely due to kinetic effects.  In 
Figure 4.2, the expanded regions compare the raw data for the ITC binding  
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Figure 4.4 P-Cdk2/cyclin A kinase inhibition by the p27-KID mutants.  (a) 
Gels showing kinase inhibition the p27-KID mutants.  (b) Inhibition curves of the 
p27-KID variants. 
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 Table 4.3 Inhibition potencies of the p27-KID mutants. 
 
 
Variant IC50  (nM) 95% confidence intervals of IC50 (nM)a 
p27-KIDwt 293.8 pM 0.17 – 0.28 
p27-KID+H 5.06 nM 3.3 – 5.1 
p27-KID-H 353 pM 0.26 – 0.33 
p27-KIDloop 15.95 nM 9.9 – 25.7 
 
 
a
 Error is reported as the 95% confidence interval of the IC50 from a curve fit of a 
triplicate data set. 
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isotherms for p27-KIDwt and p27-KIDloop.  From the figure it is clear that unlike the 
p27-KIDwt which equilibrates to a completely flat baseline between injections, the 
injection peaks of the p27-KIDloop mutant do not fully equilibrate to a flat baseline 
in the time between injections.  The equilibration time between injections is 5 
minutes.  On the other hand, during the kinase assays, P-Cdk2/cyclin A was 
mixed with p27-KIDloop and incubated for 1 hour prior to addition of ATP.  It is 
conceivable that in an hour the binding reaction reaches equilibrium explaining 
the difference between Kd and IC50.  Such a long equilibration time would not be 
practical in an ITC experiment because it would require a total experiment time of 
at least 40 hours.  In addition, the P-Cdk2/cyclin A complex would precipitate if 
kept at 25 ˚C for such an extended period of time making such an experiment 
unfeasible. 
 
4.5 Perturbation of the structure of the linker domain is deleterious to p27 
function in cells 
 Previous studies have shown that up-regulation of p27 causes cell cycle 
arrest during the G1/S cell cycle transition.111  The effects of increasing or 
decreasing the helical content of the linker domain on cell cycle arrest were 
probed by over-expressing the p27 mutants in mouse fibroblast cells 
immortalized using the NIH 3T3 protocol.232  The linker LH domain mutants were 
expressed in the context of the full-length p27 protein.  The level of protein 
expression was evaluated by measuring the GFP fluorescence of NIH 3T3 cells 
using fluorescence activated cell sorting (FACS) analysis (Figure A.7).  The DNA 
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content of cells expressing the greatest amount of GFP (top 10%) was measured 
for cell cycle analysis.  Relative to a vector only negative control, the flp27wt, 
caused cell cycle arrest and reduced the percentage of cells is S-phase from 
28.4% to 14% (Table 4.4, Figure A.8).  The mutant with the stabilized helix, 
flp27+H, also caused cell cycle arrest.  However, its cell cycle arrest capacity 
relative to flp27wt is diminished.  18.2% of the cells progressed to S-phase when 
flp27+H mutant was over-expressed.  The greatest effects on cell cycle arrest 
were observed when the structure of the linker domain was either destabilized 
(flp27-H) or completely eliminated (flp27loop).  When either flp27-H or flp27loop was 
over-expressed, 28.5% and 30.5% of the cells respectively progressed to the  
S-phase from the G1 phase.  Compared to the vector only negative control 
(28.4%), the flp27-H and the flp27loop mutants do not appear to cause cell cycle 
arrest. 
 
4.6 Summary 
 In this chapter, the thermodynamic and functional effects of perturbations 
of the structure of the linker domain of p27 have been reported.  There was a 
decrease in the enthalpy of association of p27 with the P-Cdk2/cyclin A complex 
when the structure of the linker domain was perturbed.  However, this reduction 
in enthalpy was compensated for by a proportional reduction in the entropic cost  
 associated with the folding of the p27-KID mutants on binding the P-Cdk2/cyclin 
A complex.  This compensation caused the Gibbs free energies of association of 
all the p27-KID variants to vary within a very narrow range.  The ternary  
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Table 4.4 Cell cycle analysis of cells. 
 
 
Cell cycle 
phase No plasmid 
Empty vector 
(GFP only) p27
wt
 p27+H p27-H p27loop 
G0/G1 55.3 ± 2.6 22.2 ± 2.1 57.9 ± 0.4 48.5 ± 3.0 38.7 ± 3.2 39.9 ± 2.3 
S 34.4 ± 2.1 28.4 ± 2.4 14 ± 1.0 18.2 ± 1.7 28.1 ± 1.1 30.5 ± 1.2 
G2/M 10.3 ± 1.3 49.5 ± 2.6 28.2 ± 0.6 33.3 ± 1.4 33.1 ± 3.0 29.6 ± 1.5 
 
 
The values represent the percentage of cells at the various phases of the cell 
cycle.  Triplicate experiments were done for each control and p27-KID variant. 
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complexes formed when the mutants bind to the P-Cdk2/cyclin A complex were 
thermally less stable than that formed with wild-type p27-KID.  All the mutants 
were less potent inhibitors of the P-Cdk2/cyclin A complex relative to the  
p27-KIDwt.  While enhancing the helical structure of the linker domain has a slight 
negative impact on the ability of p27 to cause cell cycle arrest, destabilizing or 
replacing this structure with a loop is deleterious to p27 function. 
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Chapter 5: Discussion 
 
5.1 The linker domain of p27 is necessary for function 
 The studies of the interactions of D1 and D2 with P-Cdk2/cyclin A support 
my hypothesis that the linker domain of p27 is necessary for function.  The 
crystal structure of the p27/Cdk2/cyclin A complex shows that the linker domain 
makes few contacts with the Cdk2/cyclin A complex.  It follows that the sum of 
the enthalpy of association of D1 with the P-Cdk2/cyclin A complex and the 
enthalpy of association of D2 with the same complex should either be equal to or 
slightly greater than (more positive) the interaction of p27 with the P-Cdk2 cyclin 
A complex.  However, the total observed enthalpy for the D1 and D2 interactions 
(-47.69 kcal mol-1) with the binary complex was less than (more negative) that for 
p27-KIDwt (-43.77 kcal mol-1).  This suggests that even though D1 and D2 bind to 
the P-Cdk2/cyclin A complex, one or both domains does (do) not make exactly 
the same contacts with P-Cdk2/cyclin A as they do in the context of p27-KIDwt.  A 
previous study reported by our laboratory suggests that it is unlikely that D1 
misfolds.197  First, the binding of D1 to the cyclin does not involve large 
conformational changes which would require overcoming many local free energy 
barriers.  Secondly, the enthalpy of the interaction D1 to the P-Cdk2/cyclin A 
complex (-16.1 ± 0.2 kcal mol-1) is very similar to that of the p27-KIDwt on binding 
cyclin A (-17.2 ± 0.3 kcal mol-1).197  This suggests that favorable contacts made in 
both cases are very similar, if not identical. 
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 On the other hand, the binding of D2 to the Cdk2 subunit of the kinase 
complex involves a number of significant conformational changes and dramatic 
folding of p27-KID and remodeling within Cdk2.  This makes it likely that the D2 
peptide does not make the same contacts with Cdk2 as does the D2 domain in 
the context of p27-KIDwt.  The results of the kinase inhibition assays confirm this 
(Figure 3.5).  ITC shows that D2 binds to the kinase complex with reduced affinity 
(Kd = 82.96 ± 17.89 nM).  However, D2 is unable to completely inhibit Cdk2 
kinase activity.  Differences in the dynamics of bound D2 peptide relative to that 
of bound D2 in the context of the p27-KID may account for the differences in 
Cdk2 kinase inhibition observed for the D2 peptide and p27-KIDwt.  I propose that 
the D2 peptide bound to Cdk2 is more dynamic than Cdk2-bound D2 in the 
context of the p27-KIDwt.  The more dynamic nature of the Cdk2-bound D2 
peptide allows some ATP molecules to access to the ATP-binding pocket thereby 
enabling the 25% residual kinase activity observed during the kinase inhibition 
assays.  I further propose that the coupling of D2 to D1 by the linker domain in 
p27-KIDwt restricts the motion of D2 on binding Cdk2.  Because of the motional 
restriction, the Cdk-binding domain of p27-KIDwt completely occludes the ATP 
binding pocket thereby blocking ATP access and ipso facto completely inhibiting 
Cdk2 kinase activity.   
 In addition to facilitating kinase inhibition, the coupling of D1 and D2 by the 
linker domain makes the interaction of p27-KIDwt with P-Cdk2/cyclin A more 
favorable than the interactions of either D1 or D2 peptides with the same 
complex.  The ∆G of the binding of p27-KIDwt to P-Cdk2/cyclin A complex (-11.61 
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± 0.30 kcal mol-1) is more favorable relative to that of either D1 (-10.06 ± 0.07 
kcal mol-1), or D2 (-9.66 ± 0.12 kcal mol-1).  This raises a question as to how the 
coupling of D1 and D2 by the linker domain makes the binding of p27-KIDwt to 
the P-Cdk2/cyclin A more favorable than the binding of D1 and D2 peptides to 
the same complex.   
 For the binding of p27-KIDwt to P-Cdk2/cyclin A to be more favorable than 
the binding of either D1 or D2, the coupling of D1 and D2 with the linker domain 
has to either cause net increase the amount of heat released (net increase in the 
enthalpy of binding) or increase the overall disorder of the system (net increase 
in entropy).  From the structure of the p27-KID/Cdk2/cyclin A it is evident that the 
linker domain makes very few contacts with either Cdk2 or cyclin A.  It is 
therefore unlikely that the linker domain decreases the free energy of the binding 
of p27-KIDwt to P-Cdk2/cyclin A (relative to the binding of D1 and D2 peptides to 
P-Cdk2/cyclin A) by causing a net increase in the enthalpy of binding. 
 The other explanation is that the coupling of D1 and D2 with the linker 
domain decreases the free energy of binding of p27-KIDwt to P-Cdk2/cyclin A, 
relative to the binding of D1 and D2 to the same complex, by causing a net 
increase in the entropy of binding.  The net change in the entropy of binding is 
determined by two components:  (i) the entropy of water resulting from the burial 
of hydrophobic side-chains (favorable entropy); and (ii) the conformational 
entropy that results from loss of translational and rotational degrees during 
protein folding (unfavorable entropy) and the motion of the protein after binding 
(favorable entropy).233,234  Since there is no significant burial of hydrophobic 
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residues within the linker domain when p27-KIDwt binds to Cdk2/cyclin A, the 
contribution of the entropy of water toward a net entropy increase should be 
minimal.  This suggests that the net increase in entropy contribution of the linker 
domain toward the binding of p27-KIDwt to P-Cdk2/cyclin A is caused by a net 
positive change in conformational entropy.  This positive change in entropy 
indicates that the contribution of the dynamics (positive entropy change) of the 
linker domain of p27 when bound to P-Cdk2/cyclin A is greater than the entropic 
contribution of the folding of the linker domain (negative entropy change).  This is 
consistent with recent results from our laboratory (unpublished results).  NMR 
analysis of p27-KID in complex with Cdk2/cyclin A has showed that the linker 
domain is dynamic even when p27 is bound to Cdk2/cyclin A.  The same has 
also been observed for the linker domain of p21-KID in a p21-KID/Cdk2/cyclin A 
complex (unpublished results).  I propose that the dynamic nature of the linker 
domain of the Cip/Kip proteins contributes significantly to the free energy of their 
association with Cdk complexes. 
 
5.2 The linker domains of the Cip/Kip proteins play similar structural roles 
despite their sequence differences 
 The sequences of the linker domains of the Cip/Kip proteins are very 
variable but have a conserved helical structure.  An analysis of the linker domain 
of each Cip/Kip protein in different species shows very high sequence 
conservation.  It is curious why nature has selected for disparate sequences in 
the linker domains of the Cip/Kip proteins.  It is reasonable to argue that if just a 
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helical structure was required to couple D1 and D2, then any sequence that 
could adopt a helical structure could have been selected for; but, this is clearly 
not the case.  This may indicate that these sequences may play well defined 
roles in the interactions of the Cip/Kip proteins with Cdk’s.  This poses a question 
as to whether the different sequences of the linker domains of the Cip/Kip 
proteins confer each protein different thermodynamic and functional properties 
when they bind to their Cdk targets.   
 ITC studies show that the free energies of association of the chimeric 
mutants on binding the P-Cdk2/cyclin A complex are very similar.  The p27-KIDwt 
has a ∆G value of -11.61 kcal mol-1, which is very close to the -11.7 ± 0.27 kcal 
mol-1 and -12.71 ± 0.17 kcal mol-1 obtained for the p27-KIDp21helix and the  
p27-KIDp57helix, respectively.  This shows that the three linker domains despite 
their differences in sequence contribute very similarly to the free energy of 
association of the Cip/Kip proteins with the P-Cdk2/cyclin A complexes.  One 
difference observed in the thermodynamic parameters is the magnitude of the 
enthalpy of binding. 
 The chimeric mutants exhibit decreased value of the enthalpy of binding 
relative to that for p27-KIDwt.  p27-KIDp21helix and p27-KIDp57helix exhibit enthalpies 
of -27.94 ± 1.26 kcal mol-1 and -31.15 ± 0.51 kcal mol-1, respectively, in 
comparison to p27-KIDwt which has an enthalpy of -43.77 kcal mol-1 on binding 
P-Cdk2/cyclin A.  The kinase assay results show that these chimeric variants are 
potent inhibitors albeit slightly less potent than p27-KIDwt.  This shows that D2 in 
the chimeric mutants binds to Cdk2 and is folded in a conformation very similar to 
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that of D2 of the p27-KIDwt.  It is unlikely that D1 of the chimeric mutants is not 
binding since the free energies of association of the chimeric mutants with  
P-Cdk2/cyclin A are more comparable to the free energy of the association of 
p27-KIDwt and P-Cdk2/cyclin A than to the free energy of association of either the 
D2 peptide and the binary complex or p27-KID with monomeric Cdk2.197  If D1 
was not binding, the free energies of the association of the chimeric mutants and 
P-Cdk2/cyclin A should reflect binding only to Cdk2.  This suggests that the 
enthalpy decrease observed in the ITC experiments is likely a result of the linker 
domains (since D1 and D2 bind) of the chimeric mutants not having exactly the 
same favorable interactions on binding P-Cdk2/cyclin A as p27-KIDwt.  While the 
loss of enthalpy contributes unfavorably to the free energy of interaction, it is 
countered by a favorable decrease in the entropic penalty associated with the 
folding on binding.  The -T∆S values for the p27-KIDp21helix and the p27-KIDp57helix 
are +16.24 ± 1.29 kcal mol-1 and +18.44 ± 0.35 kcal mol-1 respectively, in 
comparison to the greater entropic cost of +32.16 ± 1.22 kcal mol-1 of the 
interaction of p27-KIDwt with P-Cdk2/cyclin A. The proportional decrease in the 
entropic penalty effectively compensates for the enthalpic loss in the chimeric 
mutants resulting in free energy values very close to that of the p27-KIDwt.  The 
chimeric mutants exhibit an entropy-enthalpy compensation phenomenon that 
makes their interaction with the P-Cdk2/cyclin A complex favorable.   
 It has been shown that the binding of the p27-KIDwt to the P-Cdk2/cyclin A 
complex greatly stabilizes the formed ternary complex.216  The melting 
temperature of the P-Cdk2/cyclin A complex ,which is only 54.7 ± 0.6 ˚C, 
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increases to 82.3 ± 0.5 ˚C when the p27-KIDwt binds. The binding of the chimeric 
mutants stabilize the binary complex to extents very similar to that of the  
p27-KIDwt.  The ternary complexes of p27-KIDp21helix and p27-KIDp57helix have 
melting temperatures of 80.7 ± 0.2 ˚C and 80.1 ± 0.1 ˚C respectively.  This 
suggests that the non-conserved residues in the linker domain contribute 
minimally to the stability of the ternary complexes formed when the Cip/Kip 
proteins bind the binary complex.  The thermal denaturation data taken together 
with the ITC and kinase inhibition assay data suggest that the linker domains of 
the Cip/Kip proteins, despite their sequence differences, play very similar 
structural roles in binding to Cdk2/cyclin A.  
 
5.3. The role of the conserved residues in the linker domain of Cip/Kip 
proteins 
 Only 3 (Glu39, Leu41 and Arg43) out of the 22 residues in the linker 
domain are conserved.  I mutated these residues to glycines to probe their role in 
the interaction of the p27-KID with the P-Cdk2/cyclin A complex.  The 
thermodynamic parameters obtained from ITC are very similar to those of the 
p27-KIDwt.  There is a difference in the enthalpy of p27-KID∆C mutant and  
p27-KIDwt.  The enthalpy of association of p27-KID∆C is -39.65 ± 0.13 kcal mol-1, 
a decrease of 4.12 kcal mol-1 relative to that of the p27-KIDwt.  This indicates that 
the conserved residues contribute about 4 kcal mol-1 to the enthalpy of 
interaction of the p27-KIDwt with P-Cdk2/cyclin A.104  This difference is most likely 
caused by the mutation of Leu41 to Gly.  In the p27/Cdk2/cyclin A structure, 
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Leu41 is buried into the p27-KID-cyclin A interface and mutating it to a smaller 
side chain, Gly, reduces the buried surface area resulting in a reduction of the 
amount of heat released.  The other two conserved residues Glu39 and Arg43 
are largely solvent exposed.  Their mutation to Gly’s probably does not have a 
great effect on the enthalpy. However, the Gly mutations may affect the 
dynamics of the linker helix by making it more flexible since the glycine side 
chain can access a broad range of conformational states.  Like the chimeric 
mutants, this slight loss of enthalpy is compensated for and the free energy of 
association is the same as that of the p27-KIDwt within standard error.  The free 
energy of association of p27-KID∆C with the binary complex is -11.89 Kcal mol-1.
 Even though the thermodynamic parameters associated with p27-KID∆C 
mutant are very similar to those associated with p27-KIDwt, the ternary complex 
this mutant forms on binding the binary complex is significantly less stable than 
that formed by p27-KIDwt.  The binding of p27-KID∆C is associated with a Tm of 
74.1 ± 0.6 ˚C, about 8 ˚C less than that associated with p27-KIDwt.  This 
demonstrates that the conserved residues contribute significantly to the stability 
of the ternary complex. 
 The p27-KID∆C mutant is slightly less potent than the p27-KIDwt.  The IC50 
of this mutant is 2.56 nM while the p27-KIDwt has an IC50 value of 0.22 nM.  This 
clearly indicates that the effects of mutations which are very close to D1 are 
propagated along the length of the helix and are able to affect the interaction D2 
and Cdk2 resulting in the decrease in inhibition potency.  This attests to the 
dynamic nature of the linker domain of the Cip/Kip proteins.  In summary, the 
 115 
conserved residues in the linker domains of the Cip/Kip proteins contribute to the 
enthalpy of binding of p27-KID to P-Cdk2/cyclin A, the kinase activity of  
p27-KIDwt, and also play a role in increasing the thermal stability of the ternary 
complex formed on when p27 binds P-Cdk2/cyclin A. 
 
5.4 Biophysical and functional effects of increasing, decreasing, or 
eliminating the helical structure of the linker domain of p27 
 The nascent helical structure of the linker domain is conserved amongst 
members of the Cip/Kip family.  I probed the consequences of perturbing this 
conserved structure on the biophysical and functional properties of p27 by 
studying the interactions of p27 mutants, in which the helical content of the linker 
domain was either increased (p27-KID+H), decreased (p27-KID-H), or completely 
eliminated (p27-KIDloop), with the P-Cdk2/cyclin A.  The binding of p27 to 
Cdk2/cyclin A is associated with a great entropic cost.  I hypothesized that the 
preformed helix in the linker domain of p27 decreases this entropic cost. 
 Results from the ITC analysis of the binding of p27-KIDwt, p27-KID+H, and 
p27-KID-H to P-Cdk2/cyclin A disprove this hypothesis.  While the relative -T∆S 
values for the binding p27-KIDwt and p27-KID+H (+32.16 ± 1.22 kcal mol-1 and 
+22.3 ± 2.46 kcal mol-1respectively) to P-Cdk2/cyclin A seem to support this 
hypothesis, an analysis of the values of the other thermodynamic parameters 
does not.  If the p27-KID+H bound to the P-Cdk2/cyclin A complex in the same 
way as the p27-KIDwt, its association with the binary complex would be more 
favorable than that of the p27-KIDwt.  However, from my experimental 
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observation, this is not the case.  The ∆G values of the association of p27-KIDwt 
and p27-KID+H with P-Cdk2/cyclin A are -11.61 ± 0.3 kcal mol-1 and -10.42 ± 0.15 
kcal mol-1, respectively (Table 4.1).  The ∆∆G value of the association of  
p27-KID+H and P-Cdk2/cyclin A with respect to the p27-KIDwt is +1.2 kcal mol-1.  
An explanation for the less favorable free energy of association of p27-KID+H and 
P-Cdk2/cyclin A with respect to p27-KIDwt can be found in the values of the 
enthalpy that were observed for the two p27-KID variants.  The enthalpies of 
association for the interaction of p27-KIDwt and p27-KID+H with P-Cdk2/cyclin A 
are -43.77 ± 1.38 kcal mol-1 and -32.72 ± 2.57 kcal mol-1.  The heat released by 
the binding of p27-KID+H to P-Cdk2/cyclin A is less than that for the p27-KIDwt.  
This indicates the p27-KID+H mutant does not make exactly the same contacts as 
does p27-KIDwt on binding P-Cdk2/cyclin A.  Where are there differences in the 
contacts made by p27-KID+H and p27-KIDwt on binding P-Cdk2/cyclin A? 
 It is unlikely the net enthalpy decrease in the binding of p27-KID+H to  
P-Cdk2/cyclin A relative to p27-KIDwt is due to lack of binding or proper folding of 
either D1 or D2.  If D1 did not bind, the binding affinity of the interaction of  
p27-KID+H and P-Cdk2/cyclin A (Kd = 23.41 ± 6.09 nM) should be similar to the 
binding affinity of the interactions of p27 to Cdk2 (70.3 ± 23.1 nM)197or D2 
peptide to P-Cdk2/cyclin A (Kd = 82.96 ± 17.89 nM), which it does not.  The 
results from the P-Cdk2/cyclin A kinase inhibition assays (Table 4.3) show that 
D2 binds and folds, like the p27-KIDwt, into an inhibition competent conformation.  
This indicates that the reduced enthalpy observed for the binding of p27-KID+H to 
P-Cdk2/cyclin A relative to p27-KIDwt stems from differences in the favorable 
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contacts within the linker domain of p27-KID+H.  Since the linker domain of the 
p27-KID+H is already stabilized and does not need fold to the same extent as the 
p27-KIDwt on binding the P-Cdk2/cyclin A complex, the heat that is released 
during the folding of the linker domain helix of p27-KID+H on binding  
P-Cdk2/cyclin A is reduced.   
 In addition to the thermodynamic studies of the p27-KID+H, the studies of 
the p27-KID-H also show that the nascent helix of p27 does not reduce the 
entropic cost associated with binding.  The -T∆S value of p27-KID-H and  
p27-KIDwt on binding P-Cdk2/cyclin A are +18.96 ± 0.95 kcal mol-1 and +32.16 ± 
1.22 kcal mol-1, respectively.  .  If the p27-KID-H mutant folds in the same way as 
p27-KIDwt upon binding, its entropic cost should be higher than that for wild-type 
p27-KID.  This suggests that the p27-KID-H mutant does not fold to the same 
extent as p27-KIDwt.  The ability of p27-KID-H to inhibit P-Cdk2/cyclin A kinase 
activity shows that the conformation of D2 on binding the kinase complex is 
similar in both the p27-KIDwt and p27-KID-H.  The IC50 values for p27-KIDwt and 
p27-KID-H are 0.3 nM and 0.35 nM respectively (Table 4.3).  It is unlikely that D1 
in the p27-KID-H mutant is not binding since the dissociation constant of the 
binding of the D2 peptide to P-Cdk2/cyclin A (82.96 ± 17.89 nM) is much higher 
than that observed for the p27-KID-H (3.66 ± 0.91 nM).  This implies that the 
linker domain of this mutant does not fold on binding P-Cdk2/cyclin A.  This is the 
most likely cause of the decreased enthalpy of binding observed for the 
association of the p27-KID-H and the P-Cdk2/cyclin A relative to p27-KIDwt.  The 
observed enthalpies for the binding of the p27-KIDwt and p27-KID-H with the  
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P-Cdk2/cyclin A are -43.77 ± 1.38 kcal mol-1 and -30.48 ± 0.82 respectively. 
 Like the p27-KID+H and p27-KID-H mutants, the ITC thermodynamic 
parameters and the P-Cdk2/cyclin A kinase inhibition assays indicate that the D1 
and D2 domains of the p27-KIDloop mutant bind to P-Cdk2/cyclin A.  The binding 
of the D2 domain of the p27-KIDloop mutant is shown by its ability to potently and 
completely inhibit P-Cdk2/cyclin A kinase activity (IC50 = 16 nM).  In Section 5.1 
above, I discussed that complete kinase inhibition requires coupling of D1 and 
D2 by the linker domain.  The ability of the p27-KIDloop mutant to completely 
inhibit kinase activity indicates that the D1 domain of this mutant binds to the 
cyclin A subunit of P-Cdk2/cyclin A.  The -T∆S value of this mutant (+19.7 ± 1.36 
kcal mol-1) therefore shows that its linker domain does not fold to the same extent 
as the p27-KIDwt (-T∆S = +32.16 ± 1.22 kcal mol-1) on on binding P-Cdk2/cyclin 
A.  This is not surprising since this mutant was designed with residues that would 
minimize the formation of any helical structure.  Expectedly, the enthalpy of the 
p27-KIDloop mutant on binding P-Cdk2/cyclin A is less than the enthalpy of the 
interaction p27-KIDwt and the same complex.  The enthalpies of the interactions 
of p27-KIDloop and p27-KIDwt with P-Cdk2/cyclin A are -29.12 ± 1.19 kcal mol-1 
and -43.77 ± 1.38 kcal mol-1, respectively.  The results in the studies above 
suggest that the folding of the linker domain of the wild-type p27 may be an 
inherent feature of its sequence and is possibly the reason the for the 
conservation of the p27 linker domain sequence in different species. 
 Stabilization of the linker domain affects the binding affinity of p27 for  
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P-Cdk2/cyclin A.  The Kd values for the p27-KIDwt and p27-KID+H were 
determined to be 3.34 ± 1.64 nM and 23.41 ± 6.09 nM respectively.  The 
dissociation constants of the binding of the p27-KID-H and p27-KIDloop mutants to 
the P-Cdk2/cyclin A complex were 3.66 ± 0.91 nM and 138.3 ± 43.05 nM 
respectively.  The p27-KID-H mutant has the same affinity for the P-Cdk2/cyclin A 
complex as the wild-type p27-KID, suggesting that flexibility of the linker domain 
may be important for binding to the P-Cdk2/cyclin A complex.  On the other hand, 
restriction of the motions of the linker domain (p27-KID+H) decreases the affinity 
of p27 for the P-Cdk2/cyclin A complex.  However, complete elimination of the 
helical structure of the linker domain (p27-KIDloop) greatly decreases affinity for 
the P-Cdk2/cyclin A complex.  Together these data suggest that the dynamics of 
the linker domain are necessary for tight binding of p27 to P-Cdk2/cyclin A. 
 The thermal denaturation results indicate that stabilization or 
destabilization of the helical structure of the linker domain of p27 decreases the 
thermal stability of the ternary complex formed when p27 binds P-Cdk2/cyclin A.  
Melting temperatures for the ternary complexes of the p27-KIDwt, p27-KID+H,  
p27-KID-H, and p27-KIDloop were 82.3 ± 0.5 ˚C, 80.3 ± 0.2 ˚C, 78.5 ± 0.6 ˚C, and 
73.0 ± 0.3 ˚C respectively.  The thermal stability of the ternary complexes is 
determined by the difference between the free energies of the native and 
unfolded states of these complexes.  The more negative the difference obtained 
by subtracting the free energy of the native state from the free energy of the 
unfolded state, the more unstable the complex.  The destabilization of the ternary 
complexes p27-KID+H and p27-KIDloop mutants relative to that of p27-KIDwt is 
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therefore expected since the free energies of their native states are less 
favorable relative to that of the p27-KIDwt.  The Gibbs free energy values of the 
native states of the p27-KIDwt, p27-KID+H, and p27-KIDloop are -11.61 ± 0.30 kcal 
mol-1, -10.42 ± 0.15 kcal mol-1, and -9.37 ± 0.18 kcal mol-1, respectively (Table 
4.1).  On the other hand, the free energy of the native state of the ternary 
complex of the p27-KID-H mutant (∆G = -11.52 ± 0.14 kcal mol-1) has the same 
free energy as that for p27-KIDwt (-11.61 ± 0.30 kcal mol-1) within standard error.  
The destabilization of this mutant therefore stems from the stabilization of its 
unfolded state.  The destabilization of these mutants with structurally perturbed 
linker domains suggests that the structure of the wild-type linker domain of p27 is 
important for formation of a stable ternary complex. 
 Although p27-KIDwt is as potent as p27-KID-H in inhibiting P-Cdk2/cyclin A 
kinase activity, it is more potent than either p27-KID+H or p27-KIDloop.  The 
observed IC50 values for the p27-KIDwt, p27-KID-H, p27-KID+H and p27-KIDloop 
were 0.3 nM, 0.35 nM, 5 nM and 16 nM respectively.  Being potent kinase 
inhibitors, I expected these mutants to be effective in causing cell cycle arrest.  
However, cell cycle arrest analysis showed that all of the p27 mutants do not 
cause cell cycle arrest.  When flp27wt, flp27+H, flp27-H, and flp27loop are  
over-expressed in mouse fibroblasts, 14%, 18.2%, 28.1%, and 30.5% of the cells 
progressed to the S phase relative to a vector only control in which 28.4% of the 
cells progress to S phase (Table 4.4).  These results show that while stabilizing 
the linker domain of p27 in cells impairs the cell cycle arrest function, 
destabilizaing the linker domain or completely eliminating its helical structure 
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completely annuls the capacity of p27 to cause cell cycle arrest.  The raises a 
question as to why the flp27-H and flp27loop mutants cannot cause cell cycle arrest 
even though they are potent inhibitors of P-Cdk2/cyclin A kinase activity in vitro.  
One explanation is that the structural changes in the linker domains of these 
mutants may alter their specificity.  During G1/S cell cycle transition, Cdk4, Cdk6, 
Cdk1, and Cdk2 kinase complexes phosphorylate a number of downstream 
targets facilitating the progression of the cell cycle from the G1 to the S phase.  
The altered specificity of these mutants may decrease their binding to one or 
more of these Cdk complexes resulting in leaky inhibition of the G1/S transition.  
This may explain the results observed for the flp27-H and flp27loop mutants. 
The results of the cell cycle arrest analysis studies attest to the significance of 
the structure of the linker domain of p27 in biological function. 
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Appendixes 
 
 
 
A.1 Buffers 
 
 
 
Pre-scission cleavage buffer (P) 
50 mM Tris pH 7.0 
150 mM NaCl 
1 mM EDTA 
1 mM DTT 
 
 
Gel filtration buffer (GF) 
20 mM HEPES pH 7.5 
300 mM NaCl 
5 mM DTT 
 
 
Nickel binding buffer (Ni-A) 
20 mM Tris pH 8.0 
5 mM imidazole 
500 mM NaCl 
 
 
Nickel elution buffer (Ni-B) 
20 mM Tris pH 8.0 
500 mM imidazole 
500 mM NaCl 
 
 
GST binding buffer (GST-A) pH 7.3 
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
5 mM DTT 
 
 
GST elution buffer (GST-B) 
50 mM Tris pH 8.0 
10 mM reduced glutathione 
5 mM DTT 
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Q-sepahrose column binding buffer (Q-A) 
20 mM HEPES pH 7.5 
20 mM NaCl 
5 mM DTT 
 
 
Q-sepahrose column elution buffer (Q-B) 
20 mM HEPES pH 7.5 
1.0 M NaCl 
5 mM DTT 
 
 
Kinase assay buffer (KA) 
20 mM HEPES pH 7.3 
25 mM sodium b-glycerolphosphate 
15 mM MgCl2 
16 mM EGTA 
0.5 mM activated Na3VO4 
10 mM DTT 
 
 
HPLC column binding buffer (HPLC-A) 
0.1 % TFA (v/v) in H2O 
 
 
HPLC column elution buffer (HPLC-B) 
0.1 % TFA in acetonitrile 
 
 
Thrombin cleavage buffer for cyclin A (TcycA) 
20 mM Tris pH 8.0 
1.0 M NaCl 
2.5 mM CaCl2 
 
 
Nickel binding buffer for D2 peptide (Ni-A/D2) 
20 mM Na2HPO4.7H2O pH 6.5 
500 mM NaCl 
5 mM imidazole 
 
 
Nickel elution buffer for D2 peptide (Ni-B/D2) 
20 mM Na2HPO4.7H2O pH 6.5 
500 mM NaCl 
500 mM imidazole 
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Thrombin cleavage buffer (T) 
20 mM Tris pH 8.0 
50 mM Nacl 
5 mM DTT 
 
 
HPLC sample buffer (D) 
10 mM Tris pH 7.2 
5 mM NaCl 
 
 
CD buffer  
10 mM phosphate pH 7.0 
5 mM DTT 
 
 
Thermal denaturation buffer 
1 mM phosphate pH 7.0 
25 mM NaCl 
1 mM DTT 
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A.2 Growth media 
 
 
 
Luria-Bertani media (LB) 
Tryptone                      10 g 
Yeast extract                        5 g 
NaCl                       10 g 
Antibiotic (kanamycin 30 mg/ml stock, ampicillin 50 mg/ml stock)          1 mL      
H2O                                                                                                           1 L 
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A.2 Tables and figures 
 
Table A.1 Sequences of oligonucleotides used in preparing mutagenesis 
cassettes for the p27-KID mutants. 
 
 
p27-KID mutant Oligonucleotide sequences 
p27-KIDp21helix 5’GTAACGCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACAGCGAACAGCTGAGCCGCGATTGCGATGCGCTGA
TGGCGGGCTG 3’ 
 
5’CCCCGCCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCAGCGT
TCGCGCGCTTCCTGAATGCAGCCCGCCATCAGCGCATCGCAATCGCGG
CTCAGCTGTT 3’ 
 
p27-KIDp57helix 5’GTAACGCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCATGAAGAACTGAGCCGCGAACTGCAGGCGCGCC
TGGCGGAACT 3’ 
 
5’CCCCGCCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCAGCGG
TTCTGATCTTCCGCGTTCAGTTCCGCCAGGCGCGCCTGCAGTTCGCGG
CTCAGTTCTT 3’ 
 
p27-KID∆C 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACGGCGAGGGCACCGGCGACTTGGAGAAGCACT
GCAGAGACAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTTG
CGCTGGCTCGCCTCTTCCATGTCTCTGCAGTGCTTCTCCAAGTCGCCG
GTGCCCTCGC 3’ 
 
p27-KIDA10 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACGCGGCGTTAACCGCGGACTTGGAGGCGCACT
GCGCGGCGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACGCC
GCCTGGCTCGCCGCTTCCATCGCCGCGCAGTGCGCCTCCAAGTCCGCG
GTTAACGCCG 3’ 
 
(continued) 
 145 
Table A.1 (continued). 
 
 
p27-KID mutant Oligonucletide sequences 
p27-KIDA22 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACGCGGCAGCAGCGGCCGCAGCAGCAGCGGCGGCAG
CAGCCGCGGC 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCAGGCC
GCGGCCGCCGCTGCTGCCGCCGCGGCTGCTGCCGCCGCTGCTGCTGCG
GCCGCTGCTG 3’ 
 
p27-KIDSL1 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACCTGGAGCTGACCCTGGACTTGGAGCTGCACT
GCCTGCTGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTTG
CGCTGGCTCAGCAGTTCCATCAGCAGGCAGTGCAGCTCCAAGTCCAGG
GTCAGCTCCA 3’ 
 
p27-KIDSL2 a 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACGAGGAGCTGACCCTGGACTTGGAGCTGCACT
GCCTGCTGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTTG
CGCTGGCTCAGCAGTTCCATCAGCAGGCAGTGCAGCTCCAAGTCCAGG
GTCAGCTCCT 3’ 
 
p27-KIDSL3 
(p27-KID+H) 
5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACGAGGAGCTGACCAAGGACTTGGAGCTGCACT
GCCTGCTGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTTG
CGCTGGCTCAGCAGTTCCATCAGCAGGCAGTGCAGCTCCAAGTCCTTG
GTCAGCTCCT 3’ 
 
(continued) 
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Table A.1 (continued)  
 
 
p27-KID mutant Oligonucleotide sequences 
p27-KIDSL4 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACGAGGAGCTGACCAAGGACTTGGAGCTGCACT
GCAAGCTGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTTC
TTCTGGCTCAGCTCTTCCATCAGCTTGCAGTGCAGCTCCAAGTCCTTG
GTCAGCTCCT 3’ 
 
p27-KIDSL5 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACCTGGAGCTGACCCTGGACTTGGAGGAGCACT
GCCTGAAGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTTC
AGCTGGCTCTCCAGTTCCATCTTCAGGCAGTGCTCCTCCAAGTCCAGG
GTCAGCTCCA 3’ 
 
p27-KIDSL6 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACCTGCTGTTAACCCTGGACTTGGAGCTGCACT
GCCTGCTGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACAGC
AGCTGGCTCAGCAGTTCCATCAGCAGGCAGTGCAGCTCCAAGTCCAGG
GTTAACAGCA 3’ 
 
p27-KID-H 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACCACGAAGAGTTAACCGAGGACTTGGAGGAGCACT
GCGAGGAGAT 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCACTCC
TCCTGGCTCTCCTCTTCCATCTCCTCGCAGTGCTCCTCCAAGTCCTCG
GTTAACTCTT 3’ 
 
(continued) 
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Table A.1 (continued)  
 
 
p27-KID mutant Oligonucleotide sequences 
p27-KIDloop 5’GCCTCCCATATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCT
TCGGCCCGGTGGACACCAACCCGGGCAACGGCGGCCATGGCGGCACCG
GCGTGGGCGG 3’ 
 
5’CTTGGGCTCGAGGGGTTTGTGATTCTGAAAATCGAAATTCCAGCCA
TGGCCGTTGCCGCCGTTGCCGCCCACGCCGGTGCCGCCATGGCCGCCG
TTGCCCGGGT 3’ 
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Table A.2 Reagents for overlap extension PCR. 
 
 
Reagent Volume (µL) 
Forward oligonucleotide (10 ng/µl) 1 
Reverse oligonucleotide (10 ng/µl) 1 
Forward end primer (125 ng/µl) 1 
Reverse end primer (125 ng/µl) 1 
Deoxynucleosides (dNTP’s), 10 mM 1 
PCR buffer 5 
Enzymea 1 
Distilled, deionized water 40 
Total Reaction Volume 50 
 
 
a
 The enzyme used was the expand high fidelity PCR system by Roche 
(Mannheim, Germany). 
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Table A.3 Thermocycler settings for the oePCR.  
 
 
Step Temperature Time 
1 95 ˚C 45 seconds 
Start cycle 
2 95 ˚C 45 seconds 
3 55 ˚C 1 minute 
4 72 ˚C 1 minute 
Go to step 2 for 20 cycles 
5 72 ˚C 10 minutes 
6 End  
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Table A.4 Sequences of oligonucleotides and primers used in preparing 
cloning cassettes for the Cip/Kip linker domain peptides. 
 
 
Peptide Sequences 
 
p27 linker domain 
 
 
5’AAAAAACCGCGGGGTTCTTCTCATCATCATCATCATCAT
TCTTCTGGTCTGGTTCCACGTGGTTCTCATATGCATGAAGA
ACTGACTCGTGATCTGGA 3’ 
 
5’TTTTTTGAATTCTTATTACCATTTACGTTGAGAAGCTTC
TTCCATATCACGACAATGTTTTTCCAGATCACGAGTCAGTT
CTTCATGCATATGAGAAC 3’ 
 
5’AAAAAACCGCGGGGTTCTTCTCATCATC 3’ 
 
5’TTTTTTGAATTCTTATTACCATTTACGT 3’ 
 
p21 linker domain 5’AAAAAACCGCGGGGTTCTTCTCATCATCATCATCATCAT
TCTTCTGGTCTGGTTCCACGTGGTTCTCATATGAGCGAACA
GCTGAGCCGCGATTGCGA 3’ 
 
5’TTTTTTGAATTCTTATTACCAGCGTTCGCGCGCTTCCTG
AATGCAGCCCGCCATCAGCGCATCGCAATCGCGGCTCAGCT
GTTCGCTCATATGAGAAC 3’ 
 
5’AAAAAACCGCGGGGTTCTTCTCATCATC 3’ 
 
5’TTTTTTGAATTCTTATTACCAGCGTTCG 3’ 
 
p57 linker domain 5’AAAAAACCGCGGGGTTCTTCTCATCATCATCATCATCAT
TCTTCTGGTCTGGTTCCACGTGGTTCTCATATGCATGAAGA
ACTGAGCCGCGAACTGCA 3’ 
 
5’TTTTTTGAATTCTTATTACCAGCGGTTCTGATCTTCCGC
GTTCAGTTCCGCCAGGCGCGCCTGCAGTTCGCGGCTCAGTT
CTTCATGCATATGAGAAC 3’ 
 
5’AAAAAACCGCGGGGTTCTTCTCATCATC 3’ 
 
5’TTTTTTGAATTCTTATTACCAGCGGTTC 3’ 
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Table A.5 Cloning of the p27-KID linker domain mutants. 
 
 
Variant Vector(s) 
p27-KIDwt pET28, pET28GSTHis 
p27-KIDA10 pET28, pET28GSTHis 
p27-KIDA22 pET28GSTHis 
p27-KIDSL1 pET28 
p27-KIDSL2 a  
p27-KIDSL3 (p27-KID+H) pET28 
p27-KIDSL4 pET28 
p27-KIDSL5 pET28 
p27-KIDSL6 pET28, pET28GSTHis 
p27-KID-H pET28GSTHis 
p27-KIDloop pET28GSTHis 
p27-KIDp21helix pET28GSTHis 
p27-KIDp57helix pET28, pET28GSTHis 
p27-KID∆C pET28, pET28GSTHis 
 
 
a
 The cassette for the p27-KIDSL2 mutant could not be successfully cloned into 
either the pET28 or the pET28GSTHis vector. 
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Table A.6 Expression and solubility of the p27-KID linker domain mutants. 
 
 
Variant Expression vector(s) Solubility 
p27-KIDwt pET28, pET28GSTHis Soluble 
p27-KIDA10 pET28GSTHis Soluble 
p27-KIDA22 pET28GSTHis Insoluble 
p27-KIDSL1 pET28 Insoluble 
p27-KIDSL3 (p27-KID+H) pET28 Partly soluble 
p27-KIDSL4 pET28 Soluble 
p27-KIDSL5 pET28 Insoluble 
p27-KIDSL6 pET28GSTHis Insoluble 
p27-KID-H pET28GSTHis Soluble 
p27-KIDloop pET28GSTHis Soluble 
p27-KIDp21helix pET28GSTHis Soluble 
p27-KIDp57helix pET28GSTHis Soluble 
p27-KID∆C pET28GSTHis Soluble 
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Oligonucleotide template
Oligonucleotide template
Stage 1
Stage 2
AMPLIFICATION
Primer
Primer
 
 
 
Figure A.1 A schematic representation of oePCR. 
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Figure A.2 Agarose gel analysis of the oePCR for the p27 linker domain 
peptide.  The expected product size 159 bp. 
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TGTGAGCGGATACATTCCCCTCTANAAATCCNCTTTGTTTAAATTTAAGAAGGAGATATAC 
CATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
ATGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCTTCGGCCCGGTGGACCACGAAGAG 
TTAACCCGGGACTTGGAGAAGCACTGCAGAGACATGGAAGAGGCGAGCCAGCGCAAGTGG 
AATTTCGATTTTCAGAATCACAAACCCCTAGAGGGCAAGTACGAGTGGCAAGAGGTGGAG 
AAGGGCAGCTTGCCCGAGTTCTACTACAGACCCCCGCGGCCCCCCAAAGGTGCCTGCAAG 
GTGCCGGCGCAGGAGTAATAAGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGC 
ACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGC 
TGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACG 
GGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGAATGGGACGCG 
CCCTGTAGCGGNGCATTAAGCGCGGCGGCTGTGGTGGTTACGCGCCANCGNGACCGCTAC 
ACTTGCCAGCGCCCTAGCGACCGCTCCTTTCGCTTTCTTCCCTTNCTTTCTCNCCACGTT 
CGCCGGCTTTTCCTCNTCAAGCTCTAAATCGGGGGCTNCCCTTTAGGGNTCCGNTTTANT 
GCTTTACGGCACCTCNACCC 
 
 
 
Figure A.3 Sequencing results for the pET28p27-KID plasmid.  This 
sequence is only for the p27-KID coding region. 
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AGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTG 
CCGCGCGGCAGCCATATGTCAAACGTGCGAGTGTCTAACGGGAGCCCTAGCCTGGAGCGG 
ATGGACGCCAGGCAGGCGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCTTCGGCCCG 
GTGGACCACGAAGAGTTAACCCGGGACTTGGAGAAGCACTGCAGAGACATGGAAGAGGCG 
AGCCAGCGCAAGTGGAATTTCGATTTTCAGAATCACAAACCCCTAGAGGGCAAGTACGAG 
TGGCAAGAGGTGGAGAAGGGCAGCTTGCCCGAGTTCTATTACAGACCCCCGCGGCCCCCC 
AAAGGTGCCTGCAAGGTGCCGGCGCAGGAGAGCCAGGATGTCAGCGGGAGCCGCCCGGCG 
GCGCCTTTAATTGGGGCTCCGGCTAACTCTGAGGACACGCATTTGGTGGACCCAAAGACT 
GATCCGTCGGACAGCCAGACGGGGTTAGCGGAGCAATGCGCAGGAATAAGGAAGCGACCT 
GCAACCGACGATTCTTCTACTCAAAACAAAAGAGCCAACAGAACAGAAGAAAATGTTTCA 
GACGGTTCCCCAAATGCCGGTTCTGTGGAGCAGACGCCCAAGAAGCCTGGCCTCAGAAGA 
CGTCAAACGTAATAAGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGA 
 
 
 
Figure A.4 Sequencing results for the pET28flp27 plasmid.  This sequence is 
only for the flp27 coding region. 
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Figure A.5 Vector map for the MSCV-I-GFP plasmid.  The highlighted EcoRI 
site was the cloning site for the flp27 linker domain mutants. 
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MSCV-I-GFPflp27wt 
 
CTTCTCTAGGCGCCGGAATTCATGTCAAACGTGCGAGTGTCTAACGGGAGCCCTAGCCTGGAGCGGATGGACGCCAGGC
AGGCGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCTTCGGCCCGGTGGACCACGAAGAGTTAACCCGGGACTTGGA
GAAGCACTGCAGAGACATGGAAGAGGCGAGCCAGCGCAAGTGGAATTTCGATTTTCAGAATCACAAACCCCTAGAGGGC
AAGTACGAGTGGCAAGAGGTGGAGAAGGGCAGCTTGCCCGAGTTCTATTACAGACCCCCGCGGCCCCCCAAAGGTGCCT
GCAAGGTGCCGGCGCAGGAGAGCCAGGATGTCAGCGGGAGCCGCCCGGCGGCGCCTTTAATTGGGGCTCCGGCTAACTC
TGAGGACACGCATTTGGTGGACCCAAAGACTGATCCGTCGGACAGCCAGACGGGGTTAGCGGAGCAATGCGCAGGAATA
AGGAAGCGACCTGCAACCGACGATTCTTCTACTCAAAACAAAAGAGCCAACAGAACAGAAGAAAATGTTTCAGACGGTT
CCCCAAATGCCGGTTCTGTGGAGCAGACGCCCAAGAAGCCTGGCCTCAGAAGACGTCAAACGTATCCGTATGATGTGCC
GGATTATGCGTAATAAGAATTCGTTAACCTCGAGCGGGATCAATTCCGCCCCCCCCCTAACGTTACTGGCCGAAGC 
 
MSCV-I-GFPflp27SL3 (MSCV-I-GFPflp27+H) 
 
GCGCCGGANTTCATGTCAAACGTGCGAGTGTCTAACGGGAGCCCTAGCCTGGAGCGGATGGACGCCAGGCAGGCGGAGC
ACCCCAAGCCCTCGGCCTGCAGGAACCTCTTCGGCCCGGTGGACCACGAGGAGCTGACCAAGGACTTGGAGCTGCACTG
CCTGCTGATGGAACTGCTGAGCCAGCGCAAGTGGAATTTCGATTTTCAGAATCACAAACCCCTCGAGGGCAAGTACGAG
TGGCAAGAGGTGGAGAAGGGCAGCTTGCCCGAGTTCTACTACAGACCCCCGCGGCCCCCCAAAGGTGCCTGCAAGGTGC
CGGCGCAGGAGAGCCAGGATGTCAGCGGGAGCCGCCCGGCGGCGCCTTTAATTGGGGCTCCGGCTAACTCTGAGGACAC
GCATTTGGTGGACCCAAAGACTGATCCGTCGGACAGCCAGACGGGGTTAGCGGAGCAATGCGCAGGAATAAGGAAGCGA
CCTGCAACCGACGATTCTTCTACTCAAAACAAAAGAGCCAACAGAACAGAAGAAAATGTTTCAGACGGTTCCCCAAATG
CCGGTTCTGTGGAGCAGACGCCCAAGAAGCCTGGCCTCAGAAGACGTCAAACGTATCCGTATGATGTGCCGGATTATGC
GTAATAAGAATTCGTTAACCTCGAGCGGGATCAATTCCGCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAA
NGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTG 
 
MSCV-I-GFPflp27-H 
 
CCCTTTATCCAGCCCTCACTCCTTCTCTAGGCGCCGGAATTCATGTCAAACGTGCGAGTGTCTAACGGGAGCCCTAGCC
TGGAGCGGATGGACGCCAGGCAGGCGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTCTTCGGCCCGGTGGACCACGA
AGAGTTAACCGAGGACTTGGAGGAGCACTGCGAGGAGATGGAAGAGGAGAGCCAGGAGGAGTGGAATTTCGATTTTCAG
AATCACAAACCCCTCGAGGGCAAGTACGAGTGGCAAGAGGTGGAGAAGGGCAGCTTGCCCGAGTTCTACTACAGACCCC
CGCGGCCCCCCAAAGGTGCCTGCAAGGTGCCGGCGCAGGAGAGCCAGGATGTCAGCGGGAGCCGCCCGGCGGCGCCTTT
AATTGGGGCTCCGGCTAACTCTGAGGACACGCATTTGGTGGACCCAAAGACTGATCCGTCGGACAGCCAGACGGGGTTA
GCGGAACAATGCGCAGGAATAAGGAAGCGACCTGCAACCGACGATTCTTCTACTCAAAACAAAAGAGCCAACAGAACAG
AAGAAAATGTTTCAGACGGTTCCCCGAATGCCGGTTCTGTGGAGCAGACGCCCAAGAAGCCTGGCCTCAGAAGACGTCA
AACGTATCCGTATGATGTGCCGGATTATGCGTAATAAGAATTCGTTAACCTCGAGCGGGATCAATTCCGCCCCCCCCCT
AACGTTACTGGCCGAAGCC 
 
MSCV-I-GFPflp27loop 
 
GAATTCATGTCAAACGTGNGAGTGTCTAACGGGAGCCCTAGCCTGGAGCGGATGGACGCCAGGCAGGCGGAGCACCCCA
AGCCCTCGGCCTGCAGGAACCTCTTCGGCCCGGTGGACACCAACCCGGGCAACGGCGGCCATGGCGGCACCGGCGTGGG
CGGCAACGGCGGCAACGGCCATGGCTGGAATTTCGATTTTCAGAATCACAAACCCCTCGAGGGCAAGTACGAGTGGCAA
GAGGTGGAGAAGGGCAGCTTGCCCGAGTTCTACTACAGACCCCCGCGGCCCCCCAAAGGTGCCTGCAAGGTGCCGGCGC
AGGAGAGCCAGGATGTCAGCGGGAGCCGCCCGGCGGCGCCTTTAATTGGGGCTCCGGCTAACTCTGAGGACACGCATTT
GGTGGACCCAAAGACTGATCCGTCGGACAGCCAGACGGGGTTAGCGGAGCAATGCGCAGGAATAAGGAAGCGACCTGCA
ACCGACGATTCTTCTACTCAAAACAAAAGAGCCAACAGAACAGAAGAAAATGTTTCAGACGGTTCCCCAAATGCCGGTT
CTGTGGAGCAGACGCCCAAGAAGCCTGGCCTCAGAAGACGTCAAACGTATCCGTATGATGTGCCGGATTATGCGTAATA
AGAATTCGTTAACCTNGAGCGGGATCAATTCCGCCCCCCCCCTAACGTTACN 
 
 
 
Figure A.6 Sequences of the MSCV-I-GFP plasmids.  Only the region coding 
for the flp27 variants is shown.  
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Figure A.7 Flow cytometry analysis of GFP positive cells.  The percentages 
of GFP positive cells for are circumscribed with red ellipses. 
 
 
 
No GFP control
p27wt
p27+H
p27-H
p27loop
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No plasmid GFP only p27wt p27+H p27-H p27loop
34.4% S 28.4% S
14 % S 18 % S 28.1 % S
30.4 % S
G0/G1
S
G2/M
 
 
 
 
Figure A.8 Cell cycle arrest analysis of the p27-KID mutants. 
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